<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB04964</drugbank-id>
  <name>Oregovomab</name>
  <description>Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.</description>
  <cas-number>213327-37-8</cas-number>
  <unii>HX101E7L6S</unii>
  <state>liquid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3088</ref-id>
        <pubmed-id>15268682</pubmed-id>
        <citation>Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65.</citation>
      </article>
      <article>
        <ref-id>A3089</ref-id>
        <pubmed-id>15297171</pubmed-id>
        <citation>Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF: CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004 Aug;94(2):340-51.</citation>
      </article>
      <article>
        <ref-id>A3090</ref-id>
        <pubmed-id>16343178</pubmed-id>
        <citation>Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD: A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34.</citation>
      </article>
      <article>
        <ref-id>A3091</ref-id>
        <pubmed-id>17073521</pubmed-id>
        <citation>Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in ovarian cancer.</indication>
  <pharmacodynamics>Oregovomab is well tolerated and induces multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit has been observed in patients mounting a T-cell response to CA125 and/or autologous tumor. Vaccination with oregovomab may stimulate a host cytotoxic immune response against tumor cells that express CA125.</pharmacodynamics>
  <mechanism-of-action>Oregovomab targets the circulating tumour-associated antigen CA 125, which is shed from the surface of human ovarian cancer cells; the antibodies induce broad cellular and humoral immune responses against CA 125 via complex formation. Unlike free CA 125, CA 125-oregovomab complexes can prime dendritic cells, leading to downstream activation of T cells.&#13;
</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Monoclonal antibody B43.13</synonym>
    <synonym language="english" coder="">Oregovamab</synonym>
    <synonym language="english" coder="inn">Oregovomab</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>OvaRex</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents, Immunological</category>
      <mesh-id>D000074322</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>CA-125 Antigen</category>
      <mesh-id>D018394</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>Chlorotrianisene may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>Dienestrol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Mestranol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>Hexestrol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Esterified estrogens</name>
      <description>Esterified estrogens may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>Equol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>Methallenestril may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13386</drugbank-id>
      <name>Epimestrol</name>
      <description>Epimestrol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13418</drugbank-id>
      <name>Moxestrol</name>
      <description>Moxestrol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>Biochanin A may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15335</drugbank-id>
      <name>Formononetin</name>
      <description>Formononetin may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00002</drugbank-id>
      <name>Cetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Cetuximab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00028</drugbank-id>
      <name>Human immunoglobulin G</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00043</drugbank-id>
      <name>Omalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Omalizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Adalimumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of adverse effects can be increased when Abciximab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00057</drugbank-id>
      <name>Indium In-111 satumomab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of adverse effects can be increased when Infliximab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Trastuzumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Rituximab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Basiliximab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The risk or severity of adverse effects can be increased when Muromonab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00076</drugbank-id>
      <name>Digoxin Immune Fab (Ovine)</name>
      <description>The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Tositumomab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00089</drugbank-id>
      <name>Capromab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Efalizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Natalizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00110</drugbank-id>
      <name>Palivizumab</name>
      <description>The risk or severity of adverse effects can be increased when Palivizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Daclizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00113</drugbank-id>
      <name>Technetium Tc-99m arcitumomab</name>
      <description>The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The risk or severity of adverse effects can be increased when Eculizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01269</drugbank-id>
      <name>Panitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Panitumumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01270</drugbank-id>
      <name>Ranibizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ranibizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04901</drugbank-id>
      <name>Galiximab</name>
      <description>The risk or severity of adverse effects can be increased when Galiximab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04949</drugbank-id>
      <name>Pexelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Pexelizumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The risk or severity of adverse effects can be increased when Afelimomab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04958</drugbank-id>
      <name>Epratuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Epratuzumab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04962</drugbank-id>
      <name>Bectumomab</name>
      <description>The risk or severity of adverse effects can be increased when Bectumomab is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04988</drugbank-id>
      <name>IGN311</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with IGN311.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05006</drugbank-id>
      <name>Adecatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Adecatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05097</drugbank-id>
      <name>Labetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Labetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05101</drugbank-id>
      <name>Matuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Matuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05111</drugbank-id>
      <name>Fontolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Fontolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05136</drugbank-id>
      <name>Bavituximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bavituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05139</drugbank-id>
      <name>CR002</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with CR002.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05209</drugbank-id>
      <name>Rozrolimupab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Rozrolimupab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05304</drugbank-id>
      <name>Girentuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Girentuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05336</drugbank-id>
      <name>Obiltoxaximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Obiltoxaximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05405</drugbank-id>
      <name>XTL-001</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with XTL-001.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05437</drugbank-id>
      <name>NAV 1800</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with NAV 1800.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05496</drugbank-id>
      <name>Otelixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Otelixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05545</drugbank-id>
      <name>AMG 108</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with AMG 108.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05550</drugbank-id>
      <name>Iratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Iratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05555</drugbank-id>
      <name>Enokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Enokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05578</drugbank-id>
      <name>Ramucirumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ramucirumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05595</drugbank-id>
      <name>Farletuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Farletuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05656</drugbank-id>
      <name>Veltuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Veltuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05679</drugbank-id>
      <name>Ustekinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ustekinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05793</drugbank-id>
      <name>PRO-542</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with PRO-542.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05797</drugbank-id>
      <name>TNX-901</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with TNX-901.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Inotuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05892</drugbank-id>
      <name>RI 624</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with RI 624.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05915</drugbank-id>
      <name>MYO-029</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with MYO-029.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05916</drugbank-id>
      <name>CT-011</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with CT-011.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05941</drugbank-id>
      <name>Leronlimab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Leronlimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05996</drugbank-id>
      <name>Glembatumumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Glembatumumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06043</drugbank-id>
      <name>Olaratumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Olaratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06049</drugbank-id>
      <name>IPH 2101</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with IPH 2101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06050</drugbank-id>
      <name>TB-402</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with TB-402.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Caplacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06101</drugbank-id>
      <name>IMC-1C11</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with IMC-1C11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06116</drugbank-id>
      <name>Eldelumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Eldelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06162</drugbank-id>
      <name>Lumiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lumiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ipilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06192</drugbank-id>
      <name>Nimotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Nimotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06241</drugbank-id>
      <name>Clenoliximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Clenoliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06304</drugbank-id>
      <name>BIIB015</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with BIIB015.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06305</drugbank-id>
      <name>Sonepcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sonepcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06310</drugbank-id>
      <name>Motavizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Motavizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06317</drugbank-id>
      <name>Elotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Elotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with AVE9633.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06322</drugbank-id>
      <name>Carotuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Carotuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06324</drugbank-id>
      <name>XmAb 2513</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with XmAb 2513.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Coltuximab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06343</drugbank-id>
      <name>Teprotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Teprotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06360</drugbank-id>
      <name>Lucatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lucatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06366</drugbank-id>
      <name>Pertuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Pertuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06371</drugbank-id>
      <name>Siplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Siplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06467</drugbank-id>
      <name>Apolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Apolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06474</drugbank-id>
      <name>Sibrotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sibrotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06550</drugbank-id>
      <name>Bivatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bivatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06557</drugbank-id>
      <name>Lerdelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lerdelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06599</drugbank-id>
      <name>Lexatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lexatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06602</drugbank-id>
      <name>Reslizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Reslizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06606</drugbank-id>
      <name>Teplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Teplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06607</drugbank-id>
      <name>Catumaxomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Catumaxomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Denosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Volociximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06650</drugbank-id>
      <name>Ofatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ofatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08902</drugbank-id>
      <name>Raxibacumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Raxibacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09035</drugbank-id>
      <name>Nivolumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Nivolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09037</drugbank-id>
      <name>Pembrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Pembrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Anthrax immune globulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09105</drugbank-id>
      <name>Asfotase alfa</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Asfotase alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Idarucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09302</drugbank-id>
      <name>Alirocumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Alirocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09303</drugbank-id>
      <name>Evolocumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Evolocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09331</drugbank-id>
      <name>Daratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Daratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09559</drugbank-id>
      <name>Necitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11595</drugbank-id>
      <name>Atezolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Atezolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11604</drugbank-id>
      <name>Tetanus Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tetanus Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Eftrenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11621</drugbank-id>
      <name>Human Varicella-Zoster Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Human Varicella-Zoster Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11646</drugbank-id>
      <name>Conatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Conatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11657</drugbank-id>
      <name>Tabalumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tabalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11680</drugbank-id>
      <name>Ficlatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ficlatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11685</drugbank-id>
      <name>Figitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Figitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11714</drugbank-id>
      <name>Durvalumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Durvalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11715</drugbank-id>
      <name>Bapineuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bapineuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11731</drugbank-id>
      <name>Depatuxizumab mafodotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Depatuxizumab mafodotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11746</drugbank-id>
      <name>Onartuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Onartuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11756</drugbank-id>
      <name>Solanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Solanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11771</drugbank-id>
      <name>Tremelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tremelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11826</drugbank-id>
      <name>Lampalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lampalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11840</drugbank-id>
      <name>Dalotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Dalotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11849</drugbank-id>
      <name>Emibetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Emibetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11850</drugbank-id>
      <name>Ublituximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ublituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11856</drugbank-id>
      <name>Ligelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ligelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11857</drugbank-id>
      <name>Seribantumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Seribantumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11862</drugbank-id>
      <name>Landogrozumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Landogrozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11866</drugbank-id>
      <name>Romosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Romosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11884</drugbank-id>
      <name>Vadastuximab Talirine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Vadastuximab Talirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11914</drugbank-id>
      <name>Lebrikizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lebrikizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11930</drugbank-id>
      <name>Varlilumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Varlilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11945</drugbank-id>
      <name>Avelumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Avelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11959</drugbank-id>
      <name>Crenezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Crenezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11972</drugbank-id>
      <name>Rilotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Rilotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11976</drugbank-id>
      <name>Anifrolumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Anifrolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ocrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12023</drugbank-id>
      <name>Benralizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Benralizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12034</drugbank-id>
      <name>Gantenerumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Gantenerumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12053</drugbank-id>
      <name>Visilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Visilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12077</drugbank-id>
      <name>Urelumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Urelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12090</drugbank-id>
      <name>Patritumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Patritumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12102</drugbank-id>
      <name>Fulranumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Fulranumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12104</drugbank-id>
      <name>Tarextumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tarextumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12118</drugbank-id>
      <name>Sotatercept</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sotatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12119</drugbank-id>
      <name>Gevokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Gevokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12142</drugbank-id>
      <name>Duligotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Duligotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12152</drugbank-id>
      <name>Simtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Simtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12157</drugbank-id>
      <name>Fasinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Fasinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12159</drugbank-id>
      <name>Dupilumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Dupilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12169</drugbank-id>
      <name>Tralokinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tralokinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12189</drugbank-id>
      <name>Etrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Etrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12202</drugbank-id>
      <name>Zalutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Zalutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12205</drugbank-id>
      <name>Ganitumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ganitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12213</drugbank-id>
      <name>Etaracizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Etaracizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12240</drugbank-id>
      <name>Polatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Polatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12246</drugbank-id>
      <name>Inclacumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Inclacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12250</drugbank-id>
      <name>Cixutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Cixutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12261</drugbank-id>
      <name>Ascrinvacumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ascrinvacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12274</drugbank-id>
      <name>Aducanumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Aducanumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12281</drugbank-id>
      <name>Luspatercept</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Luspatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12296</drugbank-id>
      <name>GS-5745</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with GS-5745.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12317</drugbank-id>
      <name>Vanucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Vanucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12331</drugbank-id>
      <name>Labetuzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Labetuzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12335</drugbank-id>
      <name>Tanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12342</drugbank-id>
      <name>Ensituximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ensituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12344</drugbank-id>
      <name>Fezakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Fezakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12363</drugbank-id>
      <name>Dusigitumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Dusigitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12396</drugbank-id>
      <name>Fresolimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Fresolimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12413</drugbank-id>
      <name>Indusatumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Indusatumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12456</drugbank-id>
      <name>Bococizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bococizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Mirvetuximab Soravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12498</drugbank-id>
      <name>Mogamulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Mogamulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12520</drugbank-id>
      <name>Plozalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Plozalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12530</drugbank-id>
      <name>Inebilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Inebilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12534</drugbank-id>
      <name>Mavrilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Mavrilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12560</drugbank-id>
      <name>Blosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Blosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12584</drugbank-id>
      <name>Bimagrumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bimagrumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12589</drugbank-id>
      <name>Dacetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Dacetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12609</drugbank-id>
      <name>Tovetumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tovetumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12683</drugbank-id>
      <name>Lumretuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lumretuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12698</drugbank-id>
      <name>Ibalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ibalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12701</drugbank-id>
      <name>Intetumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Intetumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12718</drugbank-id>
      <name>Carlumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Carlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12734</drugbank-id>
      <name>Demcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Demcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12773</drugbank-id>
      <name>Sifalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sifalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12775</drugbank-id>
      <name>Abituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Abituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12797</drugbank-id>
      <name>Ecromeximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ecromeximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12807</drugbank-id>
      <name>Naptumomab Estafenatox</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Naptumomab Estafenatox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12815</drugbank-id>
      <name>Crotedumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Crotedumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12820</drugbank-id>
      <name>Concizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Concizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12826</drugbank-id>
      <name>Depatuxizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Depatuxizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12844</drugbank-id>
      <name>Rontalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Rontalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12845</drugbank-id>
      <name>Amatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Amatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12849</drugbank-id>
      <name>Clazakizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Clazakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12891</drugbank-id>
      <name>Ozanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ozanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12893</drugbank-id>
      <name>Sacituzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sacituzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12917</drugbank-id>
      <name>Bimekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bimekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12943</drugbank-id>
      <name>Milatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Milatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12976</drugbank-id>
      <name>Robatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Robatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13017</drugbank-id>
      <name>Rovalpituzumab Tesirine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Rovalpituzumab Tesirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13037</drugbank-id>
      <name>Namilumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Namilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13045</drugbank-id>
      <name>Racotumomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Racotumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13073</drugbank-id>
      <name>Tregalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tregalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13127</drugbank-id>
      <name>Olokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Olokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13140</drugbank-id>
      <name>Bezlotoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bezlotoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13375</drugbank-id>
      <name>Edrecolomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Edrecolomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13535</drugbank-id>
      <name>Nebacumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Nebacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13886</drugbank-id>
      <name>Human cytomegalovirus immune globulin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Human cytomegalovirus immune globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Emicizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13976</drugbank-id>
      <name>Sulesomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sulesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13979</drugbank-id>
      <name>Besilesomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Besilesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14004</drugbank-id>
      <name>Tildrakizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14012</drugbank-id>
      <name>Burosumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Burosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14039</drugbank-id>
      <name>Erenumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Erenumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14040</drugbank-id>
      <name>Eptinezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Eptinezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14041</drugbank-id>
      <name>Fremanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Fremanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14042</drugbank-id>
      <name>Galcanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Galcanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14211</drugbank-id>
      <name>Fanolesomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Fanolesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14580</drugbank-id>
      <name>BAN-2401</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with BAN-2401.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14597</drugbank-id>
      <name>Lanadelumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lanadelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14707</drugbank-id>
      <name>Cemiplimab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Cemiplimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14776</drugbank-id>
      <name>Camrelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Camrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14778</drugbank-id>
      <name>Setrusumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Setrusumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14784</drugbank-id>
      <name>Gancotamab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Gancotamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14809</drugbank-id>
      <name>Anetumab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Anetumab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14811</drugbank-id>
      <name>Isatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Isatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14824</drugbank-id>
      <name>Icrucumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Icrucumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14843</drugbank-id>
      <name>Codrituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Codrituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14864</drugbank-id>
      <name>Brolucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Brolucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14871</drugbank-id>
      <name>Xentuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Xentuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14877</drugbank-id>
      <name>Lintuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lintuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14891</drugbank-id>
      <name>Vobarilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Vobarilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14897</drugbank-id>
      <name>Parsatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Parsatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14905</drugbank-id>
      <name>Emactuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Emactuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14907</drugbank-id>
      <name>Bevacizumab zirconium Zr-89</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bevacizumab zirconium Zr-89.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14908</drugbank-id>
      <name>Refanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Refanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14947</drugbank-id>
      <name>Bermekimab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bermekimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14952</drugbank-id>
      <name>Pamrevlumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Pamrevlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14959</drugbank-id>
      <name>Opicinumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Opicinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Trastuzumab deruxtecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14967</drugbank-id>
      <name>Margetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Margetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14988</drugbank-id>
      <name>Dalantercept</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Dalantercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14997</drugbank-id>
      <name>Pateclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Pateclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15014</drugbank-id>
      <name>Gremubamab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Gremubamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15022</drugbank-id>
      <name>Apomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Apomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15044</drugbank-id>
      <name>Tafasitamab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tafasitamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15045</drugbank-id>
      <name>Ipafricept</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ipafricept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15076</drugbank-id>
      <name>Abrilumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Abrilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15089</drugbank-id>
      <name>Frovocimab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Frovocimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15090</drugbank-id>
      <name>Tezepelumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tezepelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15101</drugbank-id>
      <name>Tigatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tigatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15104</drugbank-id>
      <name>Telisotuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Telisotuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15113</drugbank-id>
      <name>Utomilumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Utomilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15118</drugbank-id>
      <name>Zolbetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Zolbetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15135</drugbank-id>
      <name>Ponezumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ponezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15160</drugbank-id>
      <name>Asunercept</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Asunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15172</drugbank-id>
      <name>Suvratoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Suvratoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15225</drugbank-id>
      <name>Mitazalimab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Mitazalimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15252</drugbank-id>
      <name>Nemolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Nemolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15277</drugbank-id>
      <name>Gedivumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Gedivumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15336</drugbank-id>
      <name>Valanafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Valanafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15349</drugbank-id>
      <name>Sofituzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Sofituzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15354</drugbank-id>
      <name>Evinacumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Evinacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15363</drugbank-id>
      <name>Istiratumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Istiratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15383</drugbank-id>
      <name>Pidilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Pidilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15397</drugbank-id>
      <name>GMA-161</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with GMA-161.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15409</drugbank-id>
      <name>Ladiratuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Ladiratuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15415</drugbank-id>
      <name>Tomaralimab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tomaralimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15428</drugbank-id>
      <name>Vesencumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Vesencumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15432</drugbank-id>
      <name>Pinatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Pinatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15441</drugbank-id>
      <name>Lulizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lulizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15443</drugbank-id>
      <name>Lorukafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Lorukafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15453</drugbank-id>
      <name>Naratuximab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Naratuximab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15559</drugbank-id>
      <name>Zenocutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Zenocutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15595</drugbank-id>
      <name>Ebola Zaire vaccine (live, attenuated)</name>
      <description>The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Oregovomab.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347909863</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Oregovomab</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0002439</id>
      <name>Mucin-16</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A3088</ref-id>
            <pubmed-id>15268682</pubmed-id>
            <citation>Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65.</citation>
          </article>
          <article>
            <ref-id>A3091</ref-id>
            <pubmed-id>17073521</pubmed-id>
            <citation>Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q8WXI7" source="Swiss-Prot">
        <name>Mucin-16</name>
        <general-function/>
        <specific-function>Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.</specific-function>
        <gene-name>MUC16</gene-name>
        <locus>19p13.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>14452-14472</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.89</theoretical-pi>
        <molecular-weight>1519158.08</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:15582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MUC16</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF414442</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8WXI7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MUC16_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CA-125</synonym>
          <synonym>CA125</synonym>
          <synonym>MUC-16</synonym>
          <synonym>Ovarian cancer-related tumor marker CA125</synonym>
          <synonym>Ovarian carcinoma antigen CA125</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049273|Mucin-16
MLKPSGLPGSSSPTRSLMTGSRSTKATPEMDSGLTGATLSPKTSTGAIVVTEHTLPFTSP
DKTLASPTSSVVGRTTQSLGVMSSALPESTSRGMTHSEQRTSPSLSPQVNGTPSRNYPAT
SMVSGLSSPRTRTSSTEGNFTKEASTYTLTVETTSGPVTEKYTVPTETSTTEGDSTETPW
DTRYIPVKITSPMKTFADSTASKENAPVSMTPAETTVTDSHTPGRTNPSFGTLYSSFLDL
SPKGTPNSRGETSLELILSTTGYPFSSPEPGSAGHSRISTSAPLSSSASVLDNKISETSI
FSGQSLTSPLSPGVPEARASTMPNSAIPFSMTLSNAETSAERVRSTISSLGTPSISTKQT
AETILTFHAFAETMDIPSTHIAKTLASEWLGSPGTLGGTSTSALTTTSPSTTLVSEETNT
HHSTSGKETEGTLNTSMTPLETSAPGEESEMTATLVPTLGFTTLDSKIRSPSQVSSSHPT
RELRTTGSTSGRQSSSTAAHGSSDILRATTSSTSKASSWTSESTAQQFSEPQHTQWVETS
PSMKTERPPASTSVAAPITTSVPSVVSGFTTLKTSSTKGIWLEETSADTLIGESTAGPTT
HQFAVPTGISMTGGSSTRGSQGTTHLLTRATASSETSADLTLATNGVPVSVSPAVSKTAA
GSSPPGGTKPSYTMVSSVIPETSSLQSSAFREGTSLGLTPLNTRHPFSSPEPDSAGHTKI
STSIPLLSSASVLEDKVSATSTFSHHKATSSITTGTPEISTKTKPSSAVLSSMTLSNAAT
SPERVRNATSPLTHPSPSGEETAGSVLTLSTSAETTDSPNIHPTGTLTSESSESPSTLSL
PSVSGVKTTFSSSTPSTHLFTSGEETEETSNPSVSQPETSVSRVRTTLASTSVPTPVFPT
MDTWPTRSAQFSSSHLVSELRATSSTSVTNSTGSALPKISHLTGTATMSQTNRDTFNDSA
APQSTTWPETSPRFKTGLPSATTTVSTSATSLSATVMVSKFTSPATSSMEATSIREPSTT
ILTTETTNGPGSMAVASTNIPIGKGYITEGRLDTSHLPIGTTASSETSMDFTMAKESVSM
SVSPSQSMDAAGSSTPGRTSQFVDTFSDDVYHLTSREITIPRDGTSSALTPQMTATHPPS
PDPGSARSTWLGILSSSPSSPTPKVTMSSTFSTQRVTTSMIMDTVETSRWNMPNLPSTTS
LTPSNIPTSGAIGKSTLVPLDTPSPATSLEASEGGLPTLSTYPESTNTPSIHLGAHASSE
SPSTIKLTMASVVKPGSYTPLTFPSIETHIHVSTARMAYSSGSSPEMTAPGETNTGSTWD
PTTYITTTDPKDTSSAQVSTPHSVRTLRTTENHPKTESATPAAYSGSPKISSSPNLTSPA
TKAWTITDTTEHSTQLHYTKLAEKSSGFETQSAPGPVSVVIPTSPTIGSSTLELTSDVPG
EPLVLAPSEQTTITLPMATWLSTSLTEEMASTDLDISSPSSPMSTFAIFPPMSTPSHELS
KSEADTSAIRNTDSTTLDQHLGIRSLGRTGDLTTVPITPLTTTWTSVIEHSTQAQDTLSA
TMSPTHVTQSLKDQTSIPASASPSHLTEVYPELGTQGRSSSEATTFWKPSTDTLSREIET
GPTNIQSTPPMDNTTTGSSSSGVTLGIAHLPIGTSSPAETSTNMALERRSSTATVSMAGT
MGLLVTSAPGRSISQSLGRVSSVLSESTTEGVTDSSKGSSPRLNTQGNTALSSSLEPSYA
EGSQMSTSIPLTSSPTTPDVEFIGGSTFWTKEVTTVMTSDISKSSARTESSSATLMSTAL
GSTENTGKEKLRTASMDLPSPTPSMEVTPWISLTLSNAPNTTDSLDLSHGVHTSSAGTLA
TDRSLNTGVTRASRLENGSDTSSKSLSMGNSTHTSMTYTEKSEVSSSIHPRPETSAPGAE
TTLTSTPGNRAISLTLPFSSIPVEEVISTGITSGPDINSAPMTHSPITPPTIVWTSTGTI
EQSTQPLHAVSSEKVSVQTQSTPYVNSVAVSASPTHENSVSSGSSTSSPYSSASLESLDS
TISRRNAITSWLWDLTTSLPTTTWPSTSLSEALSSGHSGVSNPSSTTTEFPLFSAASTSA
AKQRNPETETHGPQNTAASTLNTDASSVTGLSETPVGASISSEVPLPMAITSRSDVSGLT
SESTANPSLGTASSAGTKLTRTISLPTSESLVSFRMNKDPWTVSIPLGSHPTTNTETSIP
VNSAGPPGLSTVASDVIDTPSDGAESIPTVSFSPSPDTEVTTISHFPEKTTHSFRTISSL
THELTSRVTPIPGDWMSSAMSTKPTGASPSITLGERRTITSAAPTTSPIVLTASFTETST
VSLDNETTVKTSDILDARKTNELPSDSSSSSDLINTSIASSTMDVTKTASISPTSISGMT
ASSSPSLFSSDRPQVPTSTTETNTATSPSVSSNTYSLDGGSNVGGTPSTLPPFTITHPVE
TSSALLAWSRPVRTFSTMVSTDTASGENPTSSNSVVTSVPAPGTWTSVGSTTDLPAMGFL
KTSPAGEAHSLLASTIEPATAFTPHLSAAVVTGSSATSEASLLTTSESKAIHSSPQTPTT
PTSGANWETSATPESLLVVTETSDTTLTSKILVTDTILFSTVSTPPSKFPSTGTLSGASF
PTLLPDTPAIPLTATEPTSSLATSFDSTPLVTIASDSLGTVPETTLTMSETSNGDALVLK
TVSNPDRSIPGITIQGVTESPLHPSSTSPSKIVAPRNTTYEGSITVALSTLPAGTTGSLV
FSQSSENSETTALVDSSAGLERASVMPLTTGSQGMASSGGIRSGSTHSTGTKTFSSLPLT
MNPGEVTAMSEITTNRLTATQSTAPKGIPVKPTSAESGLLTPVSASSSPSKAFASLTTAP
PTWGIPQSTLTFEFSEVPSLDTKSASLPTPGQSLNTIPDSDASTASSSLSKSPEKNPRAR
MMTSTKAISASSFQSTGFTETPEGSASPSMAGHEPRVPTSGTGDPRYASESMSYPDPSKA
SSAMTSTSLASKLTTLFSTGQAARSGSSSSPISLSTEKETSFLSPTASTSRKTSLFLGPS
MARQPNILVHLQTSALTLSPTSTLNMSQEEPPELTSSQTIAEEEGTTAETQTLTFTPSET
PTSLLPVSSPTEPTARRKSSPETWASSISVPAKTSLVETTDGTLVTTIKMSSQAAQGNST
WPAPAEETGSSPAGTSPGSPEMSTTLKIMSSKEPSISPEIRSTVRNSPWKTPETTVPMET
TVEPVTLQSTALGSGSTSISHLPTGTTSPTKSPTENMLATERVSLSPSPPEAWTNLYSGT
PGGTRQSLATMSSVSLESPTARSITGTGQQSSPELVSKTTGMEFSMWHGSTGGTTGDTHV
SLSTSSNILEDPVTSPNSVSSLTDKSKHKTETWVSTTAIPSTVLNNKIMAAEQQTSRSVD
EAYSSTSSWSDQTSGSDITLGASPDVTNTLYITSTAQTTSLVSLPSGDQGITSLTNPSGG
KTSSASSVTSPSIGLETLRANVSAVKSDIAPTAGHLSQTSSPAEVSILDVTTAPTPGIST
TITTMGTNSISTTTPNPEVGMSTMDSTPATERRTTSTEHPSTWSSTAASDSWTVTDMTSN
LKVARSPGTISTMHTTSFLASSTELDSMSTPHGRITVIGTSLVTPSSDASAVKTETSTSE
RTLSPSDTTASTPISTFSRVQRMSISVPDILSTSWTPSSTEAEDVPVSMVSTDHASTKTD
PNTPLSTFLFDSLSTLDWDTGRSLSSATATTSAPQGATTPQELTLETMISPATSQLPFSI
GHITSAVTPAAMARSSGVTFSRPDPTSKKAEQTSTQLPTTTSAHPGQVPRSAATTLDVIP
HTAKTPDATFQRQGQTALTTEARATSDSWNEKEKSTPSAPWITEMMNSVSEDTIKEVTSS
SSVLRTLNTLDINLESGTTSSPSWKSSPYERIAPSESTTDKEAIHPSTNTVETTGWVTSS
EHASHSTIPAHSASSKLTSPVVTTSTREQAIVSMSTTTWPESTRARTEPNSFLTIELRDV
SPYMDTSSTTQTSIISSPGSTAITKGPRTEITSSKRISSSFLAQSMRSSDSPSEAITRLS
NFPAMTESGGMILAMQTSPPGATSLSAPTLDTSATASWTGTPLATTQRFTYSEKTTLFSK
GPEDTSQPSPPSVEETSSSSSLVPIHATTSPSNILLTSQGHSPSSTPPVTSVFLSETSGL
GKTTDMSRISLEPGTSLPPNLSSTAGEALSTYEASRDTKAIHHSADTAVTNMEATSSEYS
PIPGHTKPSKATSPLVTSHIMGDITSSTSVFGSSETTEIETVSSVNQGLQERSTSQVASS
ATETSTVITHVSSGDATTHVTKTQATFSSGTSISSPHQFITSTNTFTDVSTNPSTSLIMT
ESSGVTITTQTGPTGAATQGPYLLDTSTMPYLTETPLAVTPDFMQSEKTTLISKGPKDVS
WTSPPSVAETSYPSSLTPFLVTTIPPATSTLQGQHTSSPVSATSVLTSGLVKTTDMLNTS
MEPVTNSPQNLNNPSNEILATLAATTDIETIHPSINKAVTNMGTASSAHVLHSTLPVSSE
PSTATSPMVPASSMGDALASISIPGSETTDIEGEPTSSLTAGRKENSTLQEMNSTTESNI
ILSNVSVGAITEATKMEVPSFDATFIPTPAQSTKFPDIFSVASSRLSNSPPMTISTHMTT
TQTGSSGATSKIPLALDTSTLETSAGTPSVVTEGFAHSKITTAMNNDVKDVSQTNPPFQD
EASSPSSQAPVLVTTLPSSVAFTPQWHSTSSPVSMSSVLTSSLVKTAGKVDTSLETVTSS
PQSMSNTLDDISVTSAATTDIETTHPSINTVVTNVGTTGSAFESHSTVSAYPEPSKVTSP
NVTTSTMEDTTISRSIPKSSKTTRTETETTSSLTPKLRETSISQEITSSTETSTVPYKEL
TGATTEVSRTDVTSSSSTSFPGPDQSTVSLDISTETNTRLSTSPIMTESAEITITTQTGP
HGATSQDTFTMDPSNTTPQAGIHSAMTHGFSQLDVTTLMSRIPQDVSWTSPPSVDKTSSP
SSFLSSPAMTTPSLISSTLPEDKLSSPMTSLLTSGLVKITDILRTRLEPVTSSLPNFSST
SDKILATSKDSKDTKEIFPSINTEETNVKANNSGHESHSPALADSETPKATTQMVITTTV
GDPAPSTSMPVHGSSETTNIKREPTYFLTPRLRETSTSQESSFPTDTSFLLSKVPTGTIT
EVSSTGVNSSSKISTPDHDKSTVPPDTFTGEIPRVFTSSIKTKSAEMTITTQASPPESAS
HSTLPLDTSTTLSQGGTHSTVTQGFPYSEVTTLMGMGPGNVSWMTTPPVEETSSVSSLMS
SPAMTSPSPVSSTSPQSIPSSPLPVTALPTSVLVTTTDVLGTTSPESVTSSPPNLSSITH
ERPATYKDTAHTEAAMHHSTNTAVTNVGTSGSGHKSQSSVLADSETSKATPLMSTTSTLG
DTSVSTSTPNISQTNQIQTEPTASLSPRLRESSTSEKTSSTTETNTAFSYVPTGAITQAS
RTEISSSRTSISDLDRPTIAPDISTGMITRLFTSPIMTKSAEMTVTTQTTTPGATSQGIL
PWDTSTTLFQGGTHSTVSQGFPHSEITTLRSRTPGDVSWMTTPPVEETSSGFSLMSPSMT
SPSPVSSTSPESIPSSPLPVTALLTSVLVTTTNVLGTTSPEPVTSSPPNLSSPTQERLTT
YKDTAHTEAMHASMHTNTAVANVGTSISGHESQSSVPADSHTSKATSPMGITFAMGDTSV
STSTPAFFETRIQTESTSSLIPGLRDTRTSEEINTVTETSTVLSEVPTTTTTEVSRTEVI
TSSRTTISGPDHSKMSPYISTETITRLSTFPFVTGSTEMAITNQTGPIGTISQATLTLDT
SSTASWEGTHSPVTQRFPHSEETTTMSRSTKGVSWQSPPSVEETSSPSSPVPLPAITSHS
SLYSAVSGSSPTSALPVTSLLTSGRRKTIDMLDTHSELVTSSLPSASSFSGEILTSEAST
NTETIHFSENTAETNMGTTNSMHKLHSSVSIHSQPSGHTPPKVTGSMMEDAIVSTSTPGS
PETKNVDRDSTSPLTPELKEDSTALVMNSTTESNTVFSSVSLDAATEVSRAEVTYYDPTF
MPASAQSTKSPDISPEASSSHSNSPPLTISTHKTIATQTGPSGVTSLGQLTLDTSTIATS
AGTPSARTQDFVDSETTSVMNNDLNDVLKTSPFSAEEANSLSSQAPLLVTTSPSPVTSTL
QEHSTSSLVSVTSVPTPTLAKITDMDTNLEPVTRSPQNLRNTLATSEATTDTHTMHPSIN
TAVANVGTTSSPNEFYFTVSPDSDPYKATSAVVITSTSGDSIVSTSMPRSSAMKKIESET
TFSLIFRLRETSTSQKIGSSSDTSTVFDKAFTAATTEVSRTELTSSSRTSIQGTEKPTMS
PDTSTRSVTMLSTFAGLTKSEERTIATQTGPHRATSQGTLTWDTSITTSQAGTHSAMTHG
FSQLDLSTLTSRVPEYISGTSPPSVEKTSSSSSLLSLPAITSPSPVPTTLPESRPSSPVH
LTSLPTSGLVKTTDMLASVASLPPNLGSTSHKIPTTSEDIKDTEKMYPSTNIAVTNVGTT
TSEKESYSSVPAYSEPPKVTSPMVTSFNIRDTIVSTSMPGSSEITRIEMESTFSLAHGLK
GTSTSQDPIVSTEKSAVLHKLTTGATETSRTEVASSRRTSIPGPDHSTESPDISTEVIPS
LPISLGITESSNMTIITRTGPPLGSTSQGTFTLDTPTTSSRAGTHSMATQEFPHSEMTTV
MNKDPEILSWTIPPSIEKTSFSSSLMPSPAMTSPPVSSTLPKTIHTTPSPMTSLLTPSLV
MTTDTLGTSPEPTTSSPPNLSSTSHEILTTDEDTTAIEAMHPSTSTAATNVETTSSGHGS
QSSVLADSEKTKATAPMDTTSTMGHTTVSTSMSVSSETTKIKRESTYSLTPGLRETSISQ
NASFSTDTSIVLSEVPTGTTAEVSRTEVTSSGRTSIPGPSQSTVLPEISTRTMTRLFASP
TMTESAEMTIPTQTGPSGSTSQDTLTLDTSTTKSQAKTHSTLTQRFPHSEMTTLMSRGPG
DMSWQSSPSLENPSSLPSLLSLPATTSPPPISSTLPVTISSSPLPVTSLLTSSPVTTTDM
LHTSPELVTSSPPKLSHTSDERLTTGKDTTNTEAVHPSTNTAASNVEIPSSGHESPSSAL
ADSETSKATSPMFITSTQEDTTVAISTPHFLETSRIQKESISSLSPKLRETGSSVETSSA
IETSAVLSEVSIGATTEISRTEVTSSSRTSISGSAESTMLPEISTTRKIIKFPTSPILAE
SSEMTIKTQTSPPGSTSESTFTLDTSTTPSLVITHSTMTQRLPHSEITTLVSRGAGDVPR
PSSLPVEETSPPSSQLSLSAMISPSPVSSTLPASSHSSSASVTSLLTPGQVKTTEVLDAS
AEPETSSPPSLSSTSVEILATSEVTTDTEKIHPFSNTAVTKVGTSSSGHESPSSVLPDSE
TTKATSAMGTISIMGDTSVSTLTPALSNTRKIQSEPASSLTTRLRETSTSEETSLATEAN
TVLSKVSTGATTEVSRTEAISFSRTSMSGPEQSTMSQDISIGTIPRISASSVLTESAKMT
ITTQTGPSESTLESTLNLNTATTPSWVETHSIVIQGFPHPEMTTSMGRGPGGVSWPSPPF
VKETSPPSSPLSLPAVTSPHPVSTTFLAHIPPSPLPVTSLLTSGPATTTDILGTSTEPGT
SSSSSLSTTSHERLTTYKDTAHTEAVHPSTNTGGTNVATTSSGYKSQSSVLADSSPMCTT
STMGDTSVLTSTPAFLETRRIQTELASSLTPGLRESSGSEGTSSGTKMSTVLSKVPTGAT
TEISKEDVTSIPGPAQSTISPDISTRTVSWFSTSPVMTESAEITMNTHTSPLGATTQGTS
TLDTSSTTSLTMTHSTISQGFSHSQMSTLMRRGPEDVSWMSPPLLEKTRPSFSLMSSPAT
TSPSPVSSTLPESISSSPLPVTSLLTSGLAKTTDMLHKSSEPVTNSPANLSSTSVEILAT
SEVTTDTEKTHPSSNRTVTDVGTSSSGHESTSFVLADSQTSKVTSPMVITSTMEDTSVST
STPGFFETSRIQTEPTSSLTLGLRKTSSSEGTSLATEMSTVLSGVPTGATAEVSRTEVTS
SSRTSISGFAQLTVSPETSTETITRLPTSSIMTESAEMMIKTQTDPPGSTPESTHTVDIS
TTPNWVETHSTVTQRFSHSEMTTLVSRSPGDMLWPSQSSVEETSSASSLLSLPATTSPSP
VSSTLVEDFPSASLPVTSLLNPGLVITTDRMGISREPGTSSTSNLSSTSHERLTTLEDTV
DTEDMQPSTHTAVTNVRTSISGHESQSSVLSDSETPKATSPMGTTYTMGETSVSISTSDF
FETSRIQIEPTSSLTSGLRETSSSERISSATEGSTVLSEVPSGATTEVSRTEVISSRGTS
MSGPDQFTISPDISTEAITRLSTSPIMTESAESAITIETGSPGATSEGTLTLDTSTTTFW
SGTHSTASPGFSHSEMTTLMSRTPGDVPWPSLPSVEEASSVSSSLSSPAMTSTSFFSTLP
ESISSSPHPVTALLTLGPVKTTDMLRTSSEPETSSPPNLSSTSAEILATSEVTKDREKIH
PSSNTPVVNVGTVIYKHLSPSSVLADLVTTKPTSPMATTSTLGNTSVSTSTPAFPETMMT
QPTSSLTSGLREISTSQETSSATERSASLSGMPTGATTKVSRTEALSLGRTSTPGPAQST
ISPEISTETITRISTPLTTTGSAEMTITPKTGHSGASSQGTFTLDTSSRASWPGTHSAAT
HRSPHSGMTTPMSRGPEDVSWPSRPSVEKTSPPSSLVSLSAVTSPSPLYSTPSESSHSSP
LRVTSLFTPVMMKTTDMLDTSLEPVTTSPPSMNITSDESLATSKATMETEAIQLSENTAV
TQMGTISARQEFYSSYPGLPEPSKVTSPVVTSSTIKDIVSTTIPASSEITRIEMESTSTL
TPTPRETSTSQEIHSATKPSTVPYKALTSATIEDSMTQVMSSSRGPSPDQSTMSQDISTE
VITRLSTSPIKTESTEMTITTQTGSPGATSRGTLTLDTSTTFMSGTHSTASQGFSHSQMT
ALMSRTPGDVPWLSHPSVEEASSASFSLSSPVMTSSSPVSSTLPDSIHSSSLPVTSLLTS
GLVKTTELLGTSSEPETSSPPNLSSTSAEILAITEVTTDTEKLEMTNVVTSGYTHESPSS
VLADSVTTKATSSMGITYPTGDTNVLTSTPAFSDTSRIQTKSKLSLTPGLMETSISEETS
SATEKSTVLSSVPTGATTEVSRTEAISSSRTSIPGPAQSTMSSDTSMETITRISTPLTRK
ESTDMAITPKTGPSGATSQGTFTLDSSSTASWPGTHSATTQRFPQSVVTTPMSRGPEDVS
WPSPLSVEKNSPPSSLVSSSSVTSPSPLYSTPSGSSHSSPVPVTSLFTSIMMKATDMLDA
SLEPETTSAPNMNITSDESLAASKATTETEAIHVFENTAASHVETTSATEELYSSSPGFS
EPTKVISPVVTSSSIRDNMVSTTMPGSSGITRIEIESMSSLTPGLRETRTSQDITSSTET
STVLYKMPSGATPEVSRTEVMPSSRTSIPGPAQSTMSLDISDEVVTRLSTSPIMTESAEI
TITTQTGYSLATSQVTLPLGTSMTFLSGTHSTMSQGLSHSEMTNLMSRGPESLSWTSPRF
VETTRSSSSLTSLPLTTSLSPVSSTLLDSSPSSPLPVTSLILPGLVKTTEVLDTSSEPKT
SSSPNLSSTSVEIPATSEIMTDTEKIHPSSNTAVAKVRTSSSVHESHSSVLADSETTITI
PSMGITSAVDDTTVFTSNPAFSETRRIPTEPTFSLTPGFRETSTSEETTSITETSAVLYG
VPTSATTEVSMTEIMSSNRIHIPDSDQSTMSPDIITEVITRLSSSSMMSESTQMTITTQK
SSPGATAQSTLTLATTTAPLARTHSTVPPRFLHSEMTTLMSRSPENPSWKSSLFVEKTSS
SSSLLSLPVTTSPSVSSTLPQSIPSSSFSVTSLLTPGMVKTTDTSTEPGTSLSPNLSGTS
VEILAASEVTTDTEKIHPSSSMAVTNVGTTSSGHELYSSVSIHSEPSKATYPVGTPSSMA
ETSISTSMPANFETTGFEAEPFSHLTSGFRKTNMSLDTSSVTPTNTPSSPGSTHLLQSSK
TDFTSSAKTSSPDWPPASQYTEIPVDIITPFNASPSITESTGITSFPESRFTMSVTESTH
HLSTDLLPSAETISTGTVMPSLSEAMTSFATTGVPRAISGSGSPFSRTESGPGDATLSTI
AESLPSSTPVPFSSSTFTTTDSSTIPALHEITSSSATPYRVDTSLGTESSTTEGRLVMVS
TLDTSSQPGRTSSSPILDTRMTESVELGTVTSAYQVPSLSTRLTRTDGIMEHITKIPNEA
AHRGTIRPVKGPQTSTSPASPKGLHTGGTKRMETTTTALKTTTTALKTTSRATLTTSVYT
PTLGTLTPLNASMQMASTIPTEMMITTPYVFPDVPETTSSLATSLGAETSTALPRTTPSV
FNRESETTASLVSRSGAERSPVIQTLDVSSSEPDTTASWVIHPAETIPTVSKTTPNFFHS
ELDTVSSTATSHGADVSSAIPTNISPSELDALTPLVTISGTDTSTTFPTLTKSPHETETR
TTWLTHPAETSSTIPRTIPNFSHHESDATPSIATSPGAETSSAIPIMTVSPGAEDLVTSQ
VTSSGTDRNMTIPTLTLSPGEPKTIASLVTHPEAQTSSAIPTSTISPAVSRLVTSMVTSL
AAKTSTTNRALTNSPGEPATTVSLVTHPAQTSPTVPWTTSIFFHSKSDTTPSMTTSHGAE
SSSAVPTPTVSTEVPGVVTPLVTSSRAVISTTIPILTLSPGEPETTPSMATSHGEEASSA
IPTPTVSPGVPGVVTSLVTSSRAVTSTTIPILTFSLGEPETTPSMATSHGTEAGSAVPTV
LPEVPGMVTSLVASSRAVTSTTLPTLTLSPGEPETTPSMATSHGAEASSTVPTVSPEVPG
VVTSLVTSSSGVNSTSIPTLILSPGELETTPSMATSHGAEASSAVPTPTVSPGVSGVVTP
LVTSSRAVTSTTIPILTLSSSEPETTPSMATSHGVEASSAVLTVSPEVPGMVTSLVTSSR
AVTSTTIPTLTISSDEPETTTSLVTHSEAKMISAIPTLAVSPTVQGLVTSLVTSSGSETS
AFSNLTVASSQPETIDSWVAHPGTEASSVVPTLTVSTGEPFTNISLVTHPAESSSTLPRT
TSRFSHSELDTMPSTVTSPEAESSSAISTTISPGIPGVLTSLVTSSGRDISATFPTVPES
PHESEATASWVTHPAVTSTTVPRTTPNYSHSEPDTTPSIATSPGAEATSDFPTITVSPDV
PDMVTSQVTSSGTDTSITIPTLTLSSGEPETTTSFITYSETHTSSAIPTLPVSPGASKML
TSLVISSGTDSTTTFPTLTETPYEPETTAIQLIHPAETNTMVPRTTPKFSHSKSDTTLPV
AITSPGPEASSAVSTTTISPDMSDLVTSLVPSSGTDTSTTFPTLSETPYEPETTATWLTH
PAETSTTVSGTIPNFSHRGSDTAPSMVTSPGVDTRSGVPTTTIPPSIPGVVTSQVTSSAT
DTSTAIPTLTPSPGEPETTASSATHPGTQTGFTVPIRTVPSSEPDTMASWVTHPPQTSTP
VSRTTSSFSHSSPDATPVMATSPRTEASSAVLTTISPGAPEMVTSQITSSGAATSTTVPT
LTHSPGMPETTALLSTHPRTETSKTFPASTVFPQVSETTASLTIRPGAETSTALPTQTTS
SLFTLLVTGTSRVDLSPTASPGVSAKTAPLSTHPGTETSTMIPTSTLSLGLLETTGLLAT
SSSAETSTSTLTLTVSPAVSGLSSASITTDKPQTVTSWNTETSPSVTSVGPPEFSRTVTG
TTMTLIPSEMPTPPKTSHGEGVSPTTILRTTMVEATNLATTGSSPTVAKTTTTFNTLAGS
LFTPLTTPGMSTLASESVTSRTSYNHRSWISTTSSYNRRYWTPATSTPVTSTFSPGISTS
SIPSSTAATVPFMVPFTLNFTITNLQYEEDMRHPGSRKFNATERELQGLLKPLFRNSSLE
YLYSGCRLASLRPEKDSSATAVDAICTHRPDPEDLGLDRERLYWELSNLTNGIQELGPYT
LDRNSLYVNGFTHRSSMPTTSTPGTSTVDVGTSGTPSSSPSPTTAGPLLMPFTLNFTITN
LQYEEDMRRTGSRKFNTMESVLQGLLKPLFKNTSVGPLYSGCRLTLLRPEKDGAATGVDA
ICTHRLDPKSPGLNREQLYWELSKLTNDIEELGPYTLDRNSLYVNGFTHQSSVSTTSTPG
TSTVDLRTSGTPSSLSSPTIMAAGPLLVPFTLNFTITNLQYGEDMGHPGSRKFNTTERVL
QGLLGPIFKNTSVGPLYSGCRLTSLRSEKDGAATGVDAICIHHLDPKSPGLNRERLYWEL
SQLTNGIKELGPYTLDRNSLYVNGFTHRTSVPTSSTPGTSTVDLGTSGTPFSLPSPATAG
PLLVLFTLNFTITNLKYEEDMHRPGSRKFNTTERVLQTLLGPMFKNTSVGLLYSGCRLTL
LRSEKDGAATGVDAICTHRLDPKSPGVDREQLYWELSQLTNGIKELGPYTLDRNSLYVNG
FTHWIPVPTSSTPGTSTVDLGSGTPSSLPSPTTAGPLLVPFTLNFTITNLKYEEDMHCPG
SRKFNTTERVLQSLLGPMFKNTSVGPLYSGCRLTLLRSEKDGAATGVDAICTHRLDPKSP
GVDREQLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHQTSAPNTSTPGTSTVDLGTSGT
PSSLPSPTSAGPLLVPFTLNFTITNLQYEEDMHHPGSRKFNTTERVLQGLLGPMFKNTSV
GLLYSGCRLTLLRPEKNGAATGMDAICSHRLDPKSPGLNREQLYWELSQLTHGIKELGPY
TLDRNSLYVNGFTHRSSVAPTSTPGTSTVDLGTSGTPSSLPSPTTAVPLLVPFTLNFTIT
NLQYGEDMRHPGSRKFNTTERVLQGLLGPLFKNSSVGPLYSGCRLISLRSEKDGAATGVD
AICTHHLNPQSPGLDREQLYWQLSQMTNGIKELGPYTLDRNSLYVNGFTHRSSGLTTSTP
WTSTVDLGTSGTPSPVPSPTTTGPLLVPFTLNFTITNLQYEENMGHPGSRKFNITESVLQ
GLLKPLFKSTSVGPLYSGCRLTLLRPEKDGVATRVDAICTHRPDPKIPGLDRQQLYWELS
QLTHSITELGPYTLDRDSLYVNGFTQRSSVPTTSTPGTFTVQPETSETPSSLPGPTATGP
VLLPFTLNFTITNLQYEEDMRRPGSRKFNTTERVLQGLLMPLFKNTSVSSLYSGCRLTLL
RPEKDGAATRVDAVCTHRPDPKSPGLDRERLYWKLSQLTHGITELGPYTLDRHSLYVNGF
THQSSMTTTRTPDTSTMHLATSRTPASLSGPMTASPLLVLFTINFTITNLRYEENMHHPG
SRKFNTTERVLQGLLRPVFKNTSVGPLYSGCRLTLLRPKKDGAATKVDAICTYRPDPKSP
GLDREQLYWELSQLTHSITELGPYTLDRDSLYVNGFTQRSSVPTTSIPGTPTVDLGTSGT
PVSKPGPSAASPLLVLFTLNFTITNLRYEENMQHPGSRKFNTTERVLQGLLRSLFKSTSV
GPLYSGCRLTLLRPEKDGTATGVDAICTHHPDPKSPRLDREQLYWELSQLTHNITELGPY
ALDNDSLFVNGFTHRSSVSTTSTPGTPTVYLGASKTPASIFGPSAASHLLILFTLNFTIT
NLRYEENMWPGSRKFNTTERVLQGLLRPLFKNTSVGPLYSGCRLTLLRPEKDGEATGVDA
ICTHRPDPTGPGLDREQLYLELSQLTHSITELGPYTLDRDSLYVNGFTHRSSVPTTSTGV
VSEEPFTLNFTINNLRYMADMGQPGSLKFNITDNVMQHLLSPLFQRSSLGARYTGCRVIA
LRSVKNGAETRVDLLCTYLQPLSGPGLPIKQVFHELSQQTHGITRLGPYSLDKDSLYLNG
YNEPGPDEPPTTPKPATTFLPPLSEATTAMGYHLKTLTLNFTISNLQYSPDMGKGSATFN
STEGVLQHLLRPLFQKSSMGPFYLGCQLISLRPEKDGAATGVDTTCTYHPDPVGPGLDIQ
QLYWELSQLTHGVTQLGFYVLDRDSLFINGYAPQNLSIRGEYQINFHIVNWNLSNPDPTS
SEYITLLRDIQDKVTTLYKGSQLHDTFRFCLVTNLTMDSVLVTVKALFSSNLDPSLVEQV
FLDKTLNASFHWLGSTYQLVDIHVTEMESSVYQPTSSSSTQHFYLNFTITNLPYSQDKAQ
PGTTNYQRNKRNIEDALNQLFRNSSIKSYFSDCQVSTFRSVPNRHHTGVDSLCNFSPLAR
RVDRVAIYEEFLRMTRNGTQLQNFTLDRSSVLVDGYSPNRNEPLTGNSDLPFWAVILIGL
AGLLGVITCLICGVLVTTRRRKKEGEYNVQQQCPGYYQSHLDLEDLQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049274|Mucin-16 (MUC16)
ATGCTGAAACCCTCAGGCCTTCCTGGGTCATCTTCTCCCACCCGCTCCTTGATGACAGGG
AGCAGGAGCACTAAAGCCACACCAGAAATGGATTCAGGACTGACAGGAGCCACCTTGTCA
CCTAAGACATCTACAGGTGCAATCGTGGTGACAGAACATACTCTGCCCTTTACTTCCCCA
GATAAGACCTTGGCCAGTCCTACATCTTCGGTTGTGGGAAGAACCACCCAGTCTTTGGGG
GTGATGTCCTCTGCTCTCCCTGAGTCAACCTCTAGAGGAATGACACACTCCGAGCAAAGA
ACCAGCCCATCGCTGAGTCCCCAGGTCAATGGAACTCCCTCTAGGAACTACCCTGCTACA
AGCATGGTTTCAGGATTGAGTTCCCCAAGGACCAGGACCAGTTCCACAGAAGGAAATTTT
ACCAAAGAAGCATCTACATACACACTCACTGTAGAGACCACAAGTGGCCCAGTCACTGAG
AAGTACACAGTCCCCACTGAGACCTCAACAACTGAAGGTGACAGCACAGAGACCCCCTGG
GACACAAGATATATTCCTGTAAAAATCACATCTCCAATGAAAACATTTGCAGATTCAACT
GCATCCAAGGAAAATGCCCCAGTGTCTATGACTCCAGCTGAGACCACAGTTACTGACTCA
CATACTCCAGGAAGGACAAACCCATCATTTGGGACACTTTATTCTTCCTTCCTTGACCTA
TCACCTAAAGGGACCCCAAATTCCAGAGGTGAAACAAGCCTGGAACTGATTCTATCAACC
ACTGGATATCCCTTCTCCTCTCCTGAACCTGGCTCTGCAGGACACAGCAGAATAAGTACC
AGTGCGCCTTTGTCATCATCTGCTTCAGTTCTCGATAATAAAATATCAGAGACCAGCATA
TTCTCAGGCCAGAGTCTCACCTCCCCTCTGTCTCCTGGGGTGCCCGAGGCCAGAGCCAGC
ACAATGCCCAACTCAGCTATCCCTTTTTCCATGACACTAAGCAATGCAGAAACAAGTGCC
GAAAGGGTCAGAAGCACAATTTCCTCTCTGGGGACTCCATCAATATCCACAAAGCAGACA
GCAGAGACTATCCTTACCTTCCATGCCTTCGCTGAGACCATGGATATACCCAGCACCCAC
ATAGCCAAGACTTTGGCTTCAGAATGGTTGGGAAGTCCAGGTACCCTTGGTGGCACCAGC
ACTTCAGCGCTGACAACCACATCTCCATCTACCACTTTAGTCTCAGAGGAGACCAACACC
CATCACTCCACGAGTGGAAAGGAAACAGAAGGAACTTTGAATACATCTATGACTCCACTT
GAGACCTCTGCTCCTGGAGAAGAGTCCGAAATGACTGCCACCTTGGTCCCCACTCTAGGT
TTTACAACTCTTGACAGCAAGATCAGAAGTCCATCTCAGGTCTCTTCATCCCACCCAACA
AGAGAGCTCAGAACCACAGGCAGCACCTCTGGGAGGCAGAGTTCCAGCACAGCTGCCCAC
GGGAGCTCTGACATCCTGAGGGCAACCACTTCCAGCACCTCAAAAGCATCATCATGGACC
AGTGAAAGCACAGCTCAGCAATTTAGTGAACCCCAGCACACACAGTGGGTGGAGACAAGT
CCTAGCATGAAAACAGAGAGACCCCCAGCATCAACCAGTGTGGCAGCCCCTATCACCACT
TCTGTTCCCTCAGTGGTCTCTGGCTTCACCACCCTGAAGACCAGCTCCACAAAAGGGATT
TGGCTTGAAGAAACATCTGCAGACACACTCATCGGAGAATCCACAGCTGGCCCAACCACC
CATCAGTTTGCTGTTCCCACTGGGATTTCAATGACAGGAGGCAGCAGCACCAGGGGAAGC
CAGGGCACAACCCACCTACTCACCAGAGCCACAGCATCATCTGAGACATCCGCAGATTTG
ACTCTGGCCACGAACGGTGTCCCAGTCTCCGTGTCTCCAGCAGTGAGCAAGACGGCTGCT
GGCTCAAGTCCTCCAGGAGGGACAAAGCCATCATATACAATGGTTTCTTCTGTCATCCCT
GAGACATCATCTCTACAGTCCTCAGCTTTCAGGGAAGGAACCAGCCTGGGACTGACTCCA
TTAAACACTAGACATCCCTTCTCTTCCCCTGAACCAGACTCTGCAGGACACACCAAGATA
AGCACCAGCATTCCTCTGTTGTCATCTGCTTCAGTTCTTGAGGATAAAGTGTCAGCGACC
AGCACATTCTCACACCACAAAGCCACCTCATCTATTACCACAGGGACTCCTGAAATCTCA
ACAAAGACAAAGCCCAGCTCAGCCGTTCTTTCCTCCATGACCCTAAGCAATGCAGCAACA
AGTCCTGAAAGAGTCAGAAATGCAACTTCCCCTCTGACTCATCCATCTCCATCAGGGGAA
GAGACAGCAGGGAGTGTCCTCACTCTCAGCACCTCTGCTGAGACTACAGACTCACCTAAC
ATCCACCCAACTGGGACACTGACTTCAGAATCGTCAGAGAGTCCTAGCACTCTCAGCCTC
CCAAGTGTCTCTGGAGTCAAAACCACATTTTCTTCATCTACTCCTTCCACTCATCTATTT
ACTAGTGGAGAAGAAACAGAGGAAACTTCGAATCCATCTGTGTCTCAACCTGAGACTTCT
GTTTCCAGAGTAAGGACCACCTTGGCCAGCACCTCTGTCCCTACCCCAGTATTCCCCACC
ATGGACACCTGGCCTACACGTTCAGCTCAGTTCTCTTCATCCCACCTAGTGAGTGAGCTC
AGAGCTACGAGCAGTACCTCAGTTACAAACTCAACTGGTTCAGCTCTTCCTAAAATATCT
CACCTCACTGGGACGGCAACAATGTCACAGACCAATAGAGACACGTTTAATGACTCTGCT
GCACCCCAAAGCACAACTTGGCCAGAGACTAGTCCCAGATTCAAGACAGGGTTACCTTCA
GCAACAACCACTGTTTCAACCTCTGCCACTTCTCTCTCTGCTACTGTAATGGTCTCTAAA
TTCACTTCTCCAGCAACTAGTTCCATGGAAGCAACTTCTATCAGGGAACCATCAACAACC
ATCCTCACAACAGAGACCACGAATGGCCCAGGCTCTATGGCTGTGGCTTCTACCAACATC
CCAATTGGAAAGGGCTACATTACTGAAGGAAGATTGGACACAAGCCATCTGCCCATTGGA
ACCACAGCTTCCTCTGAGACATCTATGGATTTTACCATGGCCAAAGAAAGTGTCTCAATG
TCAGTATCTCCATCTCAGTCCATGGATGCTGCTGGCTCAAGCACTCCAGGAAGGACAAGC
CAATTCGTTGACACATTTTCTGATGATGTCTATCATTTAACATCCAGAGAAATTACAATA
CCTAGAGATGGAACAAGCTCAGCTCTGACTCCACAAATGACTGCAACTCACCCTCCATCT
CCTGATCCTGGCTCTGCTAGAAGCACCTGGCTTGGCATCTTGTCCTCATCTCCTTCTTCT
CCTACTCCCAAAGTCACAATGAGCTCCACATTTTCAACTCAGAGAGTCACCACAAGCATG
ATAATGGACACAGTTGAAACTAGTCGGTGGAACATGCCCAACTTACCTTCCACGACTTCC
TTGACACCAAGTAATATTCCAACAAGTGGTGCCATAGGAAAAAGCACCCTGGTTCCCTTG
GACACTCCATCTCCAGCCACATCATTGGAGGCATCAGAAGGGGGACTTCCAACCCTCAGC
ACCTACCCTGAATCAACAAACACACCCAGCATCCACCTCGGAGCACACGCTAGTTCAGAA
AGTCCAAGCACCATCAAACTTACCATGGCTTCAGTAGTAAAACCTGGCTCTTACACACCT
CTCACCTTCCCCTCAATAGAGACCCACATTCATGTATCAACAGCCAGAATGGCTTACTCT
TCTGGGTCTTCACCTGAGATGACAGCTCCTGGAGAGACTAACACTGGTAGTACCTGGGAC
CCCACCACCTACATCACCACTACGGATCCTAAGGATACAAGTTCAGCTCAGGTCTCTACA
CCCCACTCAGTGAGGACACTCAGAACCACAGAAAACCATCCAAAGACAGAGTCCGCCACC
CCAGCTGCTTACTCTGGAAGTCCTAAAATCTCAAGTTCACCCAATCTCACCAGTCCGGCC
ACAAAAGCATGGACCATCACAGACACAACTGAACACTCCACTCAATTACATTACACAAAA
TTGGCAGAAAAATCATCTGGATTTGAGACACAGTCAGCTCCAGGACCTGTCTCTGTAGTA
ATCCCTACCTCCCCTACCATTGGAAGCAGCACATTGGAACTAACTTCTGATGTCCCAGGG
GAACCCCTGGTCCTTGCTCCCAGTGAGCAGACCACAATCACTCTCCCCATGGCAACATGG
CTGAGTACCAGTTTGACAGAGGAAATGGCTTCAACAGACCTTGATATTTCAAGTCCAAGT
TCACCCATGAGTACATTTGCTATTTTTCCACCTATGTCCACACCTTCTCATGAACTTTCA
AAGTCAGAGGCAGATACCAGTGCCATTAGAAATACAGATTCAACAACGTTGGATCAGCAC
CTAGGAATCAGGAGTTTGGGCAGAACTGGGGACTTAACAACTGTTCCTATCACCCCACTG
ACAACCACGTGGACCAGTGTGATTGAACACTCAACACAAGCACAGGACACCCTTTCTGCA
ACGATGAGTCCTACTCACGTGACACAGTCACTCAAAGATCAAACATCTATACCAGCCTCA
GCATCCCCTTCCCATCTTACTGAAGTCTACCCTGAGCTCGGGACACAAGGGAGAAGCTCC
TCTGAGGCAACCACTTTTTGGAAACCATCTACAGACACACTGTCCAGAGAGATTGAGACT
GGCCCAACAAACATTCAATCCACTCCACCCATGGACAACACAACAACAGGGAGCAGTAGT
AGTGGAGTCACCCTGGGCATAGCCCACCTTCCCATAGGAACATCCTCCCCAGCTGAGACA
TCCACAAACATGGCACTGGAAAGAAGAAGTTCTACAGCCACTGTCTCTATGGCTGGGACA
ATGGGACTCCTTGTTACTAGTGCTCCAGGAAGAAGCATCAGCCAGTCATTAGGAAGAGTT
TCCTCTGTCCTTTCTGAGTCAACTACTGAAGGAGTCACAGATTCTAGTAAGGGAAGCAGC
CCAAGGCTGAACACACAGGGAAATACAGCTCTCTCCTCCTCTCTTGAACCCAGCTATGCT
GAAGGAAGCCAGATGAGCACAAGCATCCCTCTAACCTCATCTCCTACAACTCCTGATGTG
GAATTCATAGGGGGCAGCACATTTTGGACCAAGGAGGTCACCACAGTTATGACCTCAGAC
ATCTCCAAGTCTTCAGCAAGGACAGAGTCCAGCTCAGCTACCCTTATGTCCACAGCTTTG
GGAAGCACTGAAAATACAGGAAAAGAAAAACTCAGAACTGCCTCTATGGATCTTCCATCT
CCAACTCCATCAATGGAGGTGACACCATGGATTTCTCTCACTCTCAGTAATGCCCCCAAT
ACCACAGATTCACTTGACCTCAGCCATGGGGTGCACACCAGCTCTGCAGGGACTTTGGCC
ACTGACAGGTCATTGAATACTGGTGTCACTAGAGCCTCCAGATTGGAAAACGGCTCTGAT
ACCTCTTCTAAGTCCCTGTCTATGGGAAACAGCACTCACACTTCCATGACTTACACAGAG
AAGAGTGAAGTGTCTTCTTCAATCCATCCCCGACCTGAGACCTCAGCTCCTGGAGCAGAG
ACCACTTTGACTTCCACTCCTGGAAACAGGGCCATAAGCTTAACATTGCCTTTTTCATCC
ATTCCAGTGGAAGAAGTCATTTCTACAGGCATAACCTCAGGACCAGACATCAACTCAGCA
CCCATGACACATTCTCCCATCACCCCACCAACAATTGTATGGACCAGTACAGGCACAATT
GAACAGTCCACTCAACCACTACATGCAGTTTCTTCAGAAAAAGTTTCTGTGCAGACACAG
TCAACTCCATATGTCAACTCTGTGGCAGTGTCTGCTTCCCCTACCCATGAGAATTCAGTC
TCTTCTGGAAGCAGCACATCCTCTCCATATTCCTCAGCCTCACTTGAATCCTTGGATTCC
ACAATCAGTAGGAGGAATGCAATCACTTCCTGGCTATGGGACCTCACTACATCTCTCCCC
ACTACAACTTGGCCAAGTACTAGTTTATCTGAGGCACTGTCCTCAGGCCATTCTGGGGTT
TCAAACCCAAGTTCAACTACGACTGAATTTCCACTCTTTTCAGCTGCATCCACATCTGCT
GCTAAGCAAAGAAATCCAGAAACAGAGACCCATGGTCCCCAGAATACAGCCGCGAGTACT
TTGAACACTGATGCATCCTCGGTCACAGGTCTTTCTGAGACTCCTGTGGGGGCAAGTATC
AGCTCTGAAGTCCCTCTTCCAATGGCCATAACTTCTAGATCAGATGTTTCTGGCCTTACA
TCTGAGAGTACTGCTAACCCGAGTTTAGGCACAGCCTCTTCAGCAGGGACCAAATTAACT
AGGACAATATCCCTGCCCACTTCAGAGTCTTTGGTTTCCTTTAGAATGAACAAGGATCCA
TGGACAGTGTCAATCCCTTTGGGGTCCCATCCAACTACTAATACAGAAACAAGCATCCCA
GTAAACAGCGCAGGTCCACCTGGCTTGTCCACAGTAGCATCAGATGTAATTGACACACCT
TCAGATGGGGCTGAGAGTATTCCCACTGTCTCCTTTTCCCCCTCCCCTGATACTGAAGTG
ACAACTATCTCACATTTCCCAGAAAAGACAACTCATTCATTTAGAACCATTTCATCTCTC
ACTCATGAGTTGACTTCAAGAGTGACACCTATTCCTGGGGATTGGATGAGTTCAGCTATG
TCTACAAAGCCCACAGGAGCCAGTCCCTCCATTACACTGGGAGAGAGAAGGACAATCACC
TCTGCTGCTCCAACCACTTCCCCCATAGTTCTCACTGCTAGTTTCACAGAGACCAGCACA
GTTTCACTGGATAATGAAACTACAGTAAAAACCTCAGATATCCTTGACGCACGGAAAACA
AATGAGCTCCCCTCAGATAGCAGTTCTTCTTCTGATCTGATCAACACCTCCATAGCTTCT
TCAACTATGGATGTCACTAAAACAGCCTCCATCAGTCCCACTAGCATCTCAGGAATGACA
GCAAGTTCCTCCCCATCTCTCTTCTCTTCAGATAGACCCCAGGTTCCCACATCTACAACA
GAGACAAATACAGCCACCTCTCCATCTGTTTCCAGTAACACCTATTCTCTTGATGGGGGC
TCCAATGTGGGTGGCACTCCATCCACTTTACCACCCTTTACAATCACCCACCCTGTCGAG
ACAAGCTCGGCCCTATTAGCCTGGTCTAGACCAGTAAGAACTTTCAGCACCATGGTCAGC
ACTGACACTGCCTCCGGAGAAAATCCTACCTCTAGCAATTCTGTGGTGACTTCTGTTCCA
GCACCAGGTACATGGACCAGTGTAGGCAGTACTACTGACTTACCTGCCATGGGCTTTCTC
AAGACAAGTCCTGCAGGAGAGGCACACTCACTTCTAGCATCAACTATTGAACCAGCCACT
GCCTTCACTCCCCATCTCTCAGCAGCAGTGGTCACTGGATCCAGTGCTACATCAGAAGCC
AGTCTTCTCACTACGAGTGAAAGCAAAGCCATTCATTCTTCACCACAGACCCCAACTACA
CCCACCTCTGGAGCAAACTGGGAAACTTCAGCTACTCCTGAGAGCCTTTTGGTAGTCACT
GAGACTTCAGACACAACACTTACCTCAAAGATTTTGGTCACAGATACCATCTTGTTTTCA
ACTGTGTCCACGCCACCTTCTAAATTTCCAAGTACGGGGACTCTGTCTGGAGCTTCCTTC
CCTACTTTACTCCCGGACACTCCAGCCATCCCTCTCACTGCCACTGAGCCAACAAGTTCA
TTAGCTACATCCTTTGATTCCACCCCACTGGTGACTATAGCTTCGGATAGTCTTGGCACA
GTCCCAGAGACTACCCTGACCATGTCAGAGACCTCAAATGGTGATGCACTGGTTCTTAAG
ACAGTAAGTAACCCAGATAGGAGCATCCCTGGAATCACTATCCAAGGAGTAACAGAAAGT
CCACTCCATCCTTCTTCCACTTCCCCCTCTAAGATTGTTGCTCCACGGAATACAACCTAT
GAAGGTTCGATCACAGTGGCACTTTCTACTTTGCCTGCGGGAACTACTGGTTCCCTTGTA
TTCAGTCAGAGTTCTGAAAACTCAGAGACAACGGCTTTGGTAGACTCATCAGCTGGGCTT
GAGAGGGCATCTGTGATGCCACTAACCACAGGAAGCCAGGGTATGGCTAGCTCTGGAGGA
ATCAGAAGTGGGTCCACTCACTCAACTGGAACCAAAACATTTTCTTCTCTCCCTCTGACC
ATGAACCCAGGTGAGGTTACAGCCATGTCTGAAATCACCACGAACAGACTGACAGCTACT
CAATCAACAGCACCCAAAGGGATACCTGTGAAGCCCACCAGTGCTGAGTCAGGCCTCCTA
ACACCTGTCTCTGCCTCCTCAAGCCCATCAAAGGCCTTTGCCTCACTGACTACAGCTCCC
CCAACTTGGGGGATCCCACAGTCTACCTTGACATTTGAGTTTTCTGAGGTCCCAAGTTTG
GATACTAAGTCCGCTTCTTTACCAACTCCTGGACAGTCCCTGAACACCATTCCAGACTCA
GATGCAAGCACAGCATCTTCCTCACTGTCCAAGTCTCCAGAAAAAAACCCAAGGGCAAGG
ATGATGACTTCCACAAAGGCCATAAGTGCAAGCTCATTTCAATCAACAGGTTTTACTGAA
ACCCCTGAGGGATCTGCCTCCCCTTCTATGGCAGGGCATGAACCCAGAGTCCCCACTTCA
GGAACAGGGGACCCTAGATATGCCTCAGAGAGCATGTCTTATCCAGACCCAAGCAAGGCA
TCATCAGCTATGACATCGACCTCTCTTGCATCAAAACTCACAACTCTCTTCAGCACAGGT
CAAGCAGCAAGGTCTGGTTCTAGTTCCTCTCCCATAAGCCTATCCACTGAGAAAGAAACA
AGCTTCCTTTCCCCCACTGCATCCACCTCCAGAAAGACTTCACTATTTCTTGGGCCTTCC
ATGGCAAGGCAGCCCAACATATTGGTGCATCTTCAGACTTCAGCTCTGACACTTTCTCCA
ACATCCACTCTAAATATGTCCCAGGAGGAGCCTCCTGAGTTAACCTCAAGCCAGACCATT
GCAGAAGAAGAGGGAACAACAGCTGAAACACAGACGTTAACCTTCACACCATCTGAGACC
CCAACATCCTTGTTACCTGTCTCTTCTCCCACAGAACCCACAGCCAGAAGAAAGAGTTCT
CCAGAAACATGGGCAAGCTCTATTTCAGTTCCTGCCAAGACCTCCTTGGTTGAAACAACT
GATGGAACGCTAGTGACCACCATAAAGATGTCAAGCCAGGCAGCACAAGGAAATTCCACG
TGGCCTGCCCCAGCAGAGGAGACGGGGAGCAGTCCAGCAGGCACATCCCCAGGAAGCCCA
GAAATGTCTACCACTCTCAAAATCATGAGCTCCAAGGAACCCAGCATCAGCCCAGAGATC
AGGTCCACTGTGAGAAATTCTCCTTGGAAGACTCCAGAAACAACTGTTCCCATGGAGACC
ACAGTGGAACCAGTCACCCTTCAGTCCACAGCCCTAGGAAGTGGCAGCACCAGCATCTCT
CACCTGCCCACAGGAACCACATCACCAACCAAGTCACCAACAGAAAATATGTTGGCTACA
GAAAGGGTCTCCCTCTCCCCATCCCCACCTGAGGCTTGGACCAACCTTTATTCTGGAACT
CCAGGAGGGACCAGGCAGTCACTGGCCACAATGTCCTCTGTCTCCCTAGAGTCACCAACT
GCTAGAAGCATCACAGGGACTGGTCAGCAAAGCAGTCCAGAACTGGTTTCAAAGACAACT
GGAATGGAATTCTCTATGTGGCATGGCTCTACTGGAGGGACCACAGGGGACACACATGTC
TCTCTGAGCACATCTTCCAATATCCTTGAAGACCCTGTAACCAGCCCAAACTCTGTGAGC
TCATTGACAGATAAATCCAAACATAAAACCGAGACATGGGTAAGCACCACAGCCATTCCC
TCCACTGTCCTGAATAATAAGATAATGGCAGCTGAACAACAGACAAGTCGATCTGTGGAT
GAGGCTTATTCATCAACTAGTTCTTGGTCAGATCAGACATCTGGGAGTGACATCACCCTT
GGTGCATCTCCTGATGTCACAAACACATTATACATCACCTCCACAGCACAAACCACCTCA
CTAGTGTCTCTGCCCTCTGGAGACCAAGGCATTACAAGCCTCACCAATCCCTCAGGAGGA
AAAACAAGCTCTGCGTCATCTGTCACATCTCCTTCAATAGGGCTTGAGACTCTGAGGGCC
AATGTAAGTGCAGTGAAAAGTGACATTGCCCCTACTGCTGGGCATCTATCTCAGACTTCA
TCTCCTGCGGAAGTGAGCATCCTGGACGTAACCACAGCTCCTACTCCAGGTATCTCCACC
ACCATCACCACCATGGGAACCAACTCAATCTCAACTACCACACCCAACCCAGAAGTGGGT
ATGAGTACCATGGACAGCACCCCGGCCACAGAGAGGCGCACAACTTCTACAGAACACCCT
TCCACCTGGTCTTCCACAGCTGCATCAGATTCCTGGACTGTCACAGACATGACTTCAAAC
TTGAAAGTTGCAAGATCTCCTGGAACAATTTCCACAATGCATACAACTTCATTCTTAGCC
TCAAGCACTGAATTAGACTCCATGTCTACTCCCCATGGCCGTATAACTGTCATTGGAACC
AGCCTGGTCACTCCATCCTCTGATGCTTCAGCTGTAAAGACAGAGACCAGTACAAGTGAA
AGAACATTGAGTCCTTCAGACACAACTGCATCTACTCCCATCTCAACTTTTTCTCGTGTC
CAGAGGATGAGCATCTCAGTTCCTGACATTTTAAGTACAAGTTGGACTCCCAGTAGTACA
GAAGCAGAAGATGTGCCTGTTTCAATGGTTTCTACAGATCATGCTAGTACAAAGACTGAC
CCAAATACGCCCCTGTCCACTTTTCTGTTTGATTCTCTGTCCACTCTTGACTGGGACACT
GGGAGATCTCTGTCATCAGCCACAGCCACTACCTCAGCTCCTCAGGGGGCCACAACTCCC
CAGGAACTCACTTTGGAAACCATGATCAGCCCAGCTACCTCACAGTTGCCCTTCTCTATA
GGGCACATTACAAGTGCAGTCACACCAGCTGCAATGGCAAGGAGCTCTGGAGTTACTTTT
TCAAGACCAGATCCCACAAGCAAAAAGGCAGAGCAGACTTCCACTCAGCTTCCCACCACC
ACTTCTGCACATCCAGGGCAGGTGCCCAGATCAGCAGCAACAACTCTGGATGTGATCCCA
CACACAGCAAAAACTCCAGATGCAACTTTTCAGAGACAAGGGCAGACAGCTCTTACAACA
GAGGCAAGAGCTACATCTGACTCCTGGAATGAGAAAGAAAAATCAACCCCAAGTGCACCT
TGGATCACTGAGATGATGAATTCTGTCTCAGAAGATACCATCAAGGAGGTTACCAGCTCC
TCCAGTGTATTAAGGACCCTGAATACGCTGGACATAAACTTGGAATCTGGGACGACTTCA
TCCCCAAGTTGGAAAAGCAGCCCATATGAGAGAATTGCCCCTTCTGAGTCCACCACAGAC
AAAGAGGCAATTCACCCTTCTACAAACACAGTAGAGACCACAGGCTGGGTCACAAGTTCC
GAACATGCTTCTCATTCCACTATCCCAGCCCACTCAGCGTCATCCAAACTCACATCTCCA
GTGGTTACAACCTCCACCAGGGAACAAGCAATAGTTTCTATGTCAACAACCACATGGCCA
GAGTCTACAAGGGCTAGAACAGAGCCTAATTCCTTCTTGACTATTGAACTGAGGGACGTC
AGCCCTTACATGGACACCAGCTCAACCACACAAACAAGTATTATCTCTTCCCCAGGTTCC
ACTGCGATCACCAAGGGGCCTAGAACAGAAATTACCTCCTCTAAGAGAATATCCAGCTCA
TTCCTTGCCCAGTCTATGAGGTCGTCAGACAGCCCCTCAGAAGCCATCACCAGGCTGTCT
AACTTTCCTGCCATGACAGAATCTGGAGGAATGATCCTTGCTATGCAAACAAGTCCACCT
GGCGCTACATCACTAAGTGCACCTACTTTGGATACATCAGCCACAGCCTCCTGGACAGGG
ACTCCACTGGCTACGACTCAGAGATTTACATACTCAGAGAAGACCACTCTCTTTAGCAAA
GGTCCTGAGGATACATCACAGCCAAGCCCTCCCTCTGTGGAAGAAACCAGCTCTTCCTCT
TCCCTGGTACCTATCCATGCTACAACCTCGCCTTCCAATATTTTGTTGACATCACAAGGG
CACAGTCCCTCCTCTACTCCACCTGTGACCTCAGTTTTCTTGTCTGAGACCTCTGGCCTG
GGGAAGACCACAGACATGTCGAGGATAAGCTTGGAACCTGGCACAAGTTTACCTCCCAAT
TTGAGCAGTACAGCAGGTGAGGCGTTATCCACTTATGAAGCCTCCAGAGATACAAAGGCA
ATTCATCATTCTGCAGACACAGCAGTGACGAATATGGAGGCAACCAGTTCTGAATATTCT
CCTATCCCAGGCCATACAAAGCCATCCAAAGCCACATCTCCATTGGTTACCTCCCACATC
ATGGGGGACATCACTTCTTCCACATCAGTATTTGGCTCCTCCGAGACCACAGAGATTGAG
ACAGTGTCCTCTGTGAACCAGGGACTTCAGGAGAGAAGCACATCCCAGGTGGCCAGCTCT
GCTACAGAGACAAGCACTGTCATTACCCATGTGTCTAGTGGTGATGCTACTACTCATGTC
ACCAAGACACAAGCCACTTTCTCTAGCGGAACATCCATCTCAAGCCCTCATCAGTTTATA
ACTTCTACCAACACATTTACAGATGTGAGCACCAACCCCTCCACCTCTCTGATAATGACA
GAATCTTCAGGAGTGACCATCACCACCCAAACAGGTCCTACTGGAGCTGCAACACAGGGT
CCATATCTCTTGGACACATCAACCATGCCTTACTTGACAGAGACTCCATTAGCTGTGACT
CCAGATTTTATGCAATCAGAGAAGACCACTCTCATAAGCAAAGGTCCCAAGGATGTGTCC
TGGACAAGCCCTCCCTCTGTGGCAGAAACCAGCTATCCCTCTTCCCTGACACCTTTCTTG
GTCACAACCATACCTCCTGCCACTTCCACGTTACAAGGGCAACATACATCCTCTCCTGTT
TCTGCGACTTCAGTTCTTACCTCTGGACTGGTGAAGACCACAGATATGTTGAACACAAGC
ATGGAACCTGTGACCAATTCACCTCAAAATTTGAACAATCCATCAAATGAGATACTGGCC
ACTTTGGCAGCCACCACAGATATAGAGACTATTCATCCTTCCATAAACAAAGCAGTGACC
AATATGGGGACTGCCAGTTCAGCACATGTACTGCATTCCACTCTCCCAGTCAGCTCAGAA
CCATCTACAGCCACATCTCCAATGGTTCCTGCCTCCAGCATGGGGGACGCTCTTGCTTCT
ATATCAATACCTGGTTCTGAGACCACAGACATTGAGGGAGAGCCAACATCCTCCCTGACT
GCTGGACGAAAAGAGAACAGCACCCTCCAGGAGATGAACTCAACTACAGAGTCAAACATC
ATCCTCTCCAATGTGTCTGTGGGGGCTATTACTGAAGCCACAAAAATGGAAGTCCCCTCT
TTTGATGCAACATTCATACCAACTCCTGCTCAGTCAACAAAGTTCCCAGATATTTTCTCA
GTAGCCAGCAGTAGACTTTCAAACTCTCCTCCCATGACAATATCTACCCACATGACCACC
ACCCAGACAGGGTCTTCTGGAGCTACATCAAAGATTCCACTTGCCTTAGACACATCAACC
TTGGAAACCTCAGCAGGGACTCCATCAGTGGTGACTGAGGGGTTTGCCCACTCAAAAATA
ACCACTGCAATGAACAATGATGTCAAGGACGTGTCACAGACAAACCCTCCCTTTCAGGAT
GAAGCCAGCTCTCCCTCTTCTCAAGCACCTGTCCTTGTCACAACCTTACCTTCTTCTGTT
GCTTTCACACCGCAATGGCACAGTACCTCCTCTCCTGTTTCTATGTCCTCAGTTCTTACT
TCTTCACTGGTAAAGACCGCAGGCAAGGTGGATACAAGCTTAGAAACAGTGACCAGTTCA
CCTCAAAGTATGAGCAACACTTTGGATGACATATCGGTCACTTCAGCAGCCACCACAGAT
ATAGAGACAACGCATCCTTCCATAAACACAGTAGTTACCAATGTGGGGACCACCGGTTCA
GCATTTGAATCACATTCTACTGTCTCAGCTTACCCAGAGCCATCTAAAGTCACATCTCCA
AATGTTACCACCTCCACCATGGAAGACACCACAATTTCCAGATCAATACCTAAATCCTCT
AAGACTACAAGAACTGAGACTGAGACAACTTCCTCCCTGACTCCTAAACTGAGGGAGACC
AGCATCTCCCAGGAGATCACCTCGTCCACAGAGACAAGCACTGTTCCTTACAAAGAGCTC
ACTGGTGCCACTACCGAGGTATCCAGGACAGATGTCACTTCCTCTAGCAGTACATCCTTC
CCTGGCCCTGATCAGTCCACAGTGTCACTAGACATCTCCACAGAAACCAACACCAGGCTG
TCTACCTCCCCAATAATGACAGAATCTGCAGAAATAACCATCACCACCCAAACAGGTCCT
CATGGGGCTACATCACAGGATACTTTTACCATGGACCCATCAAATACAACCCCCCAGGCA
GGGATCCACTCAGCTATGACTCATGGATTTTCACAATTGGATGTGACCACTCTTATGAGC
AGAATTCCACAGGATGTATCATGGACAAGTCCTCCCTCTGTGGATAAAACCAGCTCCCCC
TCTTCCTTTCTGTCCTCACCTGCAATGACCACACCTTCCCTGATTTCTTCTACCTTACCA
GAGGATAAGCTCTCCTCTCCTATGACTTCACTTCTCACCTCTGGCCTAGTGAAGATTACA
GACATATTACGTACACGCTTGGAACCTGTGACCAGCTCACTTCCAAATTTCAGCAGCACC
TCAGATAAGATACTGGCCACTTCTAAAGACAGTAAAGACACAAAGGAAATTTTTCCTTCT
ATAAACACAGAAGAGACCAATGTGAAAGCCAACAACTCTGGACATGAATCCCATTCCCCT
GCACTGGCTGACTCAGAGACACCCAAAGCCACAACTCAAATGGTTATCACCACCACTGTG
GGAGATCCAGCTCCTTCCACATCAATGCCAGTGCATGGTTCCTCTGAGACTACAAACATT
AAGAGAGAGCCAACATATTTCTTGACTCCTAGACTGAGAGAGACCAGTACCTCTCAGGAG
TCCAGCTTTCCCACGGACACAAGTTTTCTACTTTCCAAAGTCCCCACTGGTACTATTACT
GAGGTCTCCAGTACAGGGGTCAACTCTTCTAGCAAAATTTCCACCCCAGACCATGATAAG
TCCACAGTGCCACCTGACACCTTCACAGGAGAGATCCCCAGGGTCTTCACCTCCTCTATT
AAGACAAAATCTGCAGAAATGACGATCACCACCCAAGCAAGTCCTCCTGAGTCTGCATCG
CACAGTACCCTTCCCTTGGACACATCAACCACACTTTCCCAGGGAGGGACTCATTCAACT
GTGACTCAGGGATTCCCATACTCAGAGGTGACCACTCTCATGGGCATGGGTCCTGGGAAT
GTGTCATGGATGACAACTCCCCCTGTGGAAGAAACCAGCTCTGTGTCTTCCCTGATGTCT
TCACCTGCCATGACATCCCCTTCTCCTGTTTCCTCCACATCACCACAGAGCATCCCCTCC
TCTCCTCTTCCTGTGACTGCACTTCCTACTTCTGTTCTGGTGACAACCACAGATGTGTTG
GGCACAACAAGCCCAGAGTCTGTAACCAGTTCACCTCCAAATTTGAGCAGCATCACTCAT
GAGAGACCGGCCACTTACAAAGACACTGCACACACAGAAGCCGCCATGCATCATTCCACA
AACACCGCAGTGACCAATGTAGGGACTTCCGGGTCTGGACATAAATCACAATCCTCTGTC
CTAGCTGACTCAGAGACATCGAAAGCCACACCTCTGATGAGTACCACCTCCACCCTGGGG
GACACAAGTGTTTCCACATCAACTCCTAATATCTCTCAGACTAACCAAATTCAAACAGAG
CCAACAGCATCCCTGAGCCCTAGACTGAGGGAGAGCAGCACGTCTGAGAAGACCAGCTCA
ACAACAGAGACAAATACTGCCTTTTCTTATGTGCCCACAGGTGCTATTACTCAGGCCTCC
AGAACAGAAATCTCCTCTAGCAGAACATCCATCTCAGACCTTGATCGGCCCACAATAGCA
CCCGACATCTCCACAGGAATGATCACCAGGCTCTTCACCTCCCCCATCATGACAAAATCT
GCAGAAATGACCGTCACCACTCAAACAACTACTCCTGGGGCTACATCACAGGGTATCCTT
CCCTGGGACACATCAACCACACTTTTCCAGGGAGGGACTCATTCAACCGTGTCTCAGGGA
TTCCCACACTCAGAGATAACCACTCTTCGGAGCAGAACCCCTGGAGATGTGTCATGGATG
ACAACTCCCCCTGTGGAAGAAACCAGCTCTGGGTTTTCCCTGATGTCACCTTCCATGACA
TCCCCTTCTCCTGTTTCCTCCACATCACCAGAGAGCATCCCCTCCTCTCCTCTCCCTGTG
ACTGCACTTCTTACTTCTGTTCTGGTGACAACCACAAATGTATTGGGCACAACAAGCCCA
GAGCCCGTAACGAGTTCACCTCCAAATTTAAGCAGCCCCACACAGGAGAGACTGACCACT
TACAAAGACACTGCGCACACAGAAGCCATGCATGCTTCCATGCATACAAACACTGCAGTG
GCCAACGTGGGGACCTCCATTTCTGGACATGAATCACAATCTTCTGTCCCAGCTGATTCA
CACACATCCAAAGCCACATCTCCAATGGGTATCACCTTCGCCATGGGGGATACAAGTGTT
TCTACATCAACTCCTGCCTTCTTTGAGACTAGAATTCAGACTGAATCAACATCCTCTTTG
ATTCCTGGATTAAGGGACACCAGGACGTCTGAGGAGATCAACACTGTGACAGAGACCAGC
ACTGTCCTTTCAGAAGTGCCCACTACTACTACTACTGAGGTCTCCAGGACAGAAGTTATC
ACTTCCAGCAGAACAACCATCTCAGGGCCTGATCATTCCAAAATGTCACCCTACATCTCC
ACAGAAACCATCACCAGGCTCTCCACTTTTCCTTTTGTAACAGGATCCACAGAAATGGCC
ATCACCAACCAAACAGGTCCTATAGGGACTATCTCACAGGCTACCCTTACCCTGGACACA
TCAAGCACAGCTTCCTGGGAAGGGACTCACTCACCTGTGACTCAGAGATTTCCACACTCA
GAGGAGACCACTACTATGAGCAGAAGTACTAAGGGCGTGTCATGGCAAAGCCCTCCCTCT
GTGGAAGAAACCAGTTCTCCTTCTTCCCCAGTGCCTTTACCTGCAATAACCTCACATTCA
TCTCTTTATTCCGCAGTATCAGGAAGTAGCCCCACTTCTGCTCTCCCTGTGACTTCCCTT
CTCACCTCTGGCAGGAGGAAGACCATAGACATGTTGGACACACACTCAGAACTTGTGACC
AGCTCCTTACCAAGTGCAAGTAGCTTCTCAGGTGAGATACTCACTTCTGAAGCCTCCACA
AATACAGAGACAATTCACTTTTCAGAGAACACAGCAGAAACCAATATGGGGACCACCAAT
TCTATGCATAAACTACATTCCTCTGTCTCAATCCACTCCCAGCCATCCGGACACACACCT
CCAAAGGTTACTGGATCTATGATGGAGGACGCTATTGTTTCCACATCAACACCTGGTTCT
CCTGAGACTAAAAATGTTGACAGAGACTCAACATCCCCTCTGACTCCTGAACTGAAAGAG
GACAGCACCGCCCTGGTGATGAACTCAACTACAGAGTCAAACACTGTTTTCTCCAGTGTG
TCCCTGGATGCTGCTACTGAGGTCTCCAGGGCAGAAGTCACCTACTATGATCCTACATTC
ATGCCAGCTTCTGCTCAGTCAACAAAGTCCCCAGACATTTCACCTGAAGCCAGCAGCAGT
CATTCTAACTCTCCTCCCTTGACAATATCTACACACAAGACCATCGCCACACAAACAGGT
CCTTCTGGGGTGACATCTCTTGGCCAACTGACCCTGGACACATCAACCATAGCCACCTCA
GCAGGAACTCCATCAGCCAGAACTCAGGATTTTGTAGATTCAGAAACAACCAGTGTCATG
AACAATGATCTCAATGATGTGTTGAAGACAAGCCCTTTCTCTGCAGAAGAAGCCAACTCT
CTCTCTTCTCAGGCACCTCTCCTTGTGACAACCTCACCTTCTCCTGTAACTTCCACATTG
CAAGAGCACAGTACCTCCTCTCTTGTTTCTGTGACCTCAGTACCCACCCCTACACTGGCG
AAGATCACAGACATGGACACAAACTTAGAACCTGTGACTCGTTCACCTCAAAATTTAAGG
AACACCTTGGCCACTTCAGAAGCCACCACAGATACACACACAATGCATCCTTCTATAAAC
ACAGCAGTGGCCAATGTGGGGACCACCAGTTCACCAAATGAATTCTATTTTACTGTCTCA
CCTGACTCAGACCCATATAAAGCCACATCCGCAGTAGTTATCACTTCCACCTCGGGGGAC
TCAATAGTTTCCACATCAATGCCTAGATCCTCTGCGATGAAAAAGATTGAGTCTGAGACA
ACTTTCTCCCTGATATTTAGACTGAGGGAGACTAGCACCTCCCAGAAAATTGGCTCATCC
TCAGACACAAGCACGGTCTTTGACAAAGCATTCACTGCTGCTACTACTGAGGTCTCCAGA
ACAGAACTCACCTCCTCTAGCAGAACATCCATCCAAGGCACTGAAAAGCCCACAATGTCA
CCGGACACCTCCACAAGATCTGTCACCATGCTTTCTACTTTTGCTGGCCTGACAAAATCC
GAAGAAAGGACCATTGCCACCCAAACAGGTCCTCATAGGGCGACATCACAGGGTACCCTT
ACCTGGGACACATCAATCACAACCTCACAGGCAGGGACCCACTCAGCTATGACTCATGGA
TTTTCACAATTAGATTTGTCCACTCTTACGAGTAGAGTTCCTGAGTACATATCAGGGACA
AGCCCACCCTCTGTGGAAAAAACCAGCTCTTCCTCTTCCCTTCTGTCTTTACCAGCAATA
ACCTCACCGTCCCCTGTACCTACTACATTACCAGAAAGTAGGCCGTCTTCTCCTGTTCAT
CTGACTTCACTCCCCACCTCTGGCCTAGTGAAGACCACAGATATGCTGGCATCTGTGGCC
AGTTTACCTCCAAACTTGGGCAGCACCTCACATAAGATACCGACTACTTCAGAAGACATT
AAAGATACAGAGAAAATGTATCCTTCCACAAACATAGCAGTAACCAATGTGGGGACCACC
ACTTCTGAAAAGGAATCTTATTCGTCTGTCCCAGCCTACTCAGAACCACCCAAAGTCACC
TCTCCAATGGTTACCTCTTTCAACATAAGGGACACCATTGTTTCCACATCCATGCCTGGC
TCCTCTGAGATTACAAGGATTGAGATGGAGTCAACATTCTCCCTGGCTCATGGGCTGAAG
GGAACCAGCACCTCCCAGGACCCCATCGTATCCACAGAGAAAAGTGCTGTCCTTCACAAG
TTGACCACTGGTGCTACTGAGACCTCTAGGACAGAAGTTGCCTCTTCTAGAAGAACATCC
ATTCCAGGCCCTGATCATTCCACAGAGTCACCAGACATCTCCACTGAAGTGATCCCCAGC
CTGCCTATCTCCCTTGGCATTACAGAATCTTCAAATATGACCATCATCACTCGAACAGGT
CCTCCTCTTGGCTCTACATCACAGGGCACATTTACCTTGGACACACCAACTACATCCTCC
AGGGCAGGAACACACTCGATGGCGACTCAGGAATTTCCACACTCAGAAATGACCACTGTC
ATGAACAAGGACCCTGAGATTCTATCATGGACAATCCCTCCTTCTATAGAGAAAACCAGC
TTCTCCTCTTCCCTGATGCCTTCACCAGCCATGACTTCACCTCCTGTTTCCTCAACATTA
CCAAAGACCATTCACACCACTCCTTCTCCTATGACCTCACTGCTCACCCCTAGCCTAGTG
ATGACCACAGACACATTGGGCACAAGCCCAGAACCTACAACCAGTTCACCTCCAAATTTG
AGCAGTACCTCACATGAGATACTGACAACAGATGAAGACACCACAGCTATAGAAGCCATG
CATCCTTCCACAAGCACAGCAGCGACTAATGTGGAAACCACCAGTTCTGGACATGGGTCA
CAATCCTCTGTCCTAGCTGACTCAGAAAAAACCAAGGCCACAGCTCCAATGGATACCACC
TCCACCATGGGGCATACAACTGTTTCCACATCAATGTCTGTTTCCTCTGAGACTACAAAA
ATTAAGAGAGAGTCAACATATTCCTTGACTCCTGGACTGAGAGAGACCAGCATTTCCCAA
AATGCCAGCTTTTCCACTGACACAAGTATTGTTCTTTCAGAAGTCCCCACTGGTACTACT
GCTGAGGTCTCCAGGACAGAAGTCACCTCCTCTGGTAGAACATCCATCCCTGGCCCTTCT
CAGTCCACAGTTTTGCCAGAAATATCCACAAGAACAATGACAAGGCTCTTTGCCTCGCCC
ACCATGACAGAATCAGCAGAAATGACCATCCCCACTCAAACAGGTCCTTCTGGGTCTACC
TCACAGGATACCCTTACCTTGGACACATCCACCACAAAGTCCCAGGCAAAGACTCATTCA
ACTTTGACTCAGAGATTTCCACACTCAGAGATGACCACTCTCATGAGCAGAGGTCCTGGA
GATATGTCATGGCAAAGCTCTCCCTCTCTGGAAAATCCCAGCTCTCTCCCTTCCCTGCTG
TCTTTACCTGCCACAACCTCACCTCCTCCCATTTCCTCCACATTACCAGTGACTATCTCC
TCCTCTCCTCTTCCTGTGACTTCACTTCTCACCTCTAGCCCGGTAACGACCACAGACATG
TTACACACAAGCCCAGAACTTGTAACCAGTTCACCTCCAAAGCTGAGCCACACTTCAGAT
GAGAGACTGACCACTGGCAAGGACACCACAAATACAGAAGCTGTGCATCCTTCCACAAAC
ACAGCAGCGTCCAATGTGGAGATTCCCAGCTCTGGACATGAATCCCCTTCCTCTGCCTTA
GCTGACTCAGAGACATCCAAAGCCACATCACCAATGTTTATTACCTCCACCCAGGAGGAT
ACAACTGTTGCCATATCAACCCCTCACTTCTTGGAGACTAGCAGAATTCAGAAAGAGTCA
ATTTCCTCCCTGAGCCCTAAATTGAGGGAGACAGGCAGTTCTGTGGAGACAAGCTCAGCC
ATAGAGACAAGTGCTGTCCTTTCTGAAGTGTCCATTGGTGCTACTACTGAGATCTCCAGG
ACAGAAGTCACCTCCTCTAGCAGAACATCCATCTCTGGTTCTGCTGAGTCCACAATGTTG
CCAGAAATATCCACCACAAGAAAAATCATTAAGTTCCCTACTTCCCCCATCCTGGCAGAA
TCATCAGAAATGACCATCAAGACCCAAACAAGTCCTCCTGGGTCTACATCAGAGAGTACC
TTTACATTAGACACATCAACCACTCCCTCCTTGGTAATAACCCATTCGACTATGACTCAG
AGATTGCCACACTCAGAGATAACCACTCTTGTGAGTAGAGGTGCTGGGGATGTGCCACGG
CCCAGCTCTCTCCCTGTGGAAGAAACAAGCCCTCCATCTTCCCAGCTGTCTTTATCTGCC
ATGATCTCACCTTCTCCTGTTTCTTCCACATTACCAGCAAGTAGCCACTCCTCTTCTGCT
TCTGTGACTTCACTTCTCACACCAGGCCAAGTGAAGACTACTGAGGTGTTGGACGCAAGT
GCAGAACCTGAAACCAGTTCACCTCCAAGTTTGAGCAGCACCTCAGTTGAAATACTGGCC
ACCTCTGAAGTCACCACAGATACGGAGAAAATTCATCCTTTCTCAAACACGGCAGTAACC
AAAGTTGGAACTTCCAGTTCTGGACATGAATCCCCTTCCTCTGTCCTACCTGACTCAGAG
ACAACCAAAGCCACATCGGCAATGGGTACCATCTCCATTATGGGGGATACAAGTGTTTCT
ACATTAACTCCTGCCTTATCTAACACTAGGAAAATTCAGTCAGAGCCAGCTTCCTCACTG
ACCACCAGATTGAGGGAGACCAGCACCTCTGAAGAGACCAGCTTAGCCACAGAAGCAAAC
ACTGTTCTTTCTAAAGTGTCCACTGGTGCTACTACTGAGGTCTCCAGGACAGAAGCCATC
TCCTTTAGCAGAACATCCATGTCAGGCCCTGAGCAGTCCACAATGTCACAAGACATCTCC
ATAGGAACCATCCCCAGGATTTCTGCCTCCTCTGTCCTGACAGAATCTGCAAAAATGACC
ATCACAACCCAAACAGGTCCTTCGGAGTCTACACTAGAAAGTACCCTTAATTTGAACACA
GCAACCACACCCTCTTGGGTGGAAACCCACTCTATAGTAATTCAGGGATTTCCACACCCA
GAGATGACCACTTCCATGGGCAGAGGTCCTGGAGGTGTGTCATGGCCTAGCCCTCCCTTT
GTGAAAGAAACCAGCCCTCCATCCTCCCCGCTGTCTTTACCTGCCGTGACCTCACCTCAT
CCTGTTTCCACCACATTCCTAGCACATATCCCCCCCTCTCCCCTTCCTGTGACTTCACTT
CTCACCTCTGGCCCGGCGACAACCACAGATATCTTGGGTACAAGCACAGAACCTGGAACC
AGTTCATCTTCAAGTTTGAGCACCACCTCCCATGAGAGACTGACCACTTACAAAGACACT
GCACATACAGAAGCCGTGCATCCTTCCACAAACACAGGAGGGACCAATGTGGCAACCACC
AGCTCTGGATATAAATCACAGTCCTCTGTCCTAGCTGACTCATCTCCAATGTGTACCACC
TCCACCATGGGGGATACAAGTGTTCTCACATCAACTCCTGCCTTCCTTGAGACTAGGAGG
ATTCAGACAGAGCTAGCTTCCTCCCTGACCCCTGGATTGAGGGAGTCCAGCGGCTCTGAA
GGGACCAGCTCAGGCACCAAGATGAGCACTGTCCTCTCTAAAGTGCCCACTGGTGCTACT
ACTGAGATCTCCAAGGAAGACGTCACCTCCATCCCAGGTCCCGCTCAATCCACAATATCA
CCAGACATCTCCACAAGAACCGTCAGCTGGTTCTCTACATCCCCTGTCATGACAGAATCA
GCAGAAATAACCATGAACACCCATACAAGTCCTTTAGGGGCCACAACACAAGGCACCAGT
ACTTTGGACACGTCAAGCACAACCTCTTTGACAATGACACACTCAACTATATCTCAAGGA
TTTTCACACTCACAGATGAGCACTCTTATGAGGAGGGGTCCTGAGGATGTATCATGGATG
AGCCCTCCCCTTCTGGAAAAAACTAGACCTTCCTTTTCTCTGATGTCTTCACCAGCCACA
ACTTCACCTTCTCCTGTTTCCTCCACATTACCAGAGAGCATCTCTTCCTCTCCTCTTCCT
GTGACTTCACTCCTCACGTCTGGCTTGGCAAAAACTACAGATATGTTGCACAAAAGCTCA
GAACCTGTAACCAACTCACCTGCAAATTTGAGCAGCACCTCAGTTGAAATACTGGCCACC
TCTGAAGTCACCACAGATACAGAGAAAACTCATCCTTCTTCAAACAGAACAGTGACCGAT
GTGGGGACCTCCAGTTCTGGACATGAATCCACTTCCTTTGTCCTAGCTGACTCACAGACA
TCCAAAGTCACATCTCCAATGGTTATTACCTCCACCATGGAGGATACGAGTGTCTCCACA
TCAACTCCTGGCTTTTTTGAGACTAGCAGAATTCAGACAGAACCAACATCCTCCCTGACC
CTTGGACTGAGAAAGACCAGCAGCTCTGAGGGGACCAGCTTAGCCACAGAGATGAGCACT
GTCCTTTCTGGAGTGCCCACTGGTGCCACTGCTGAAGTCTCCAGGACAGAAGTCACCTCC
TCTAGCAGAACATCCATCTCAGGCTTTGCTCAGCTCACAGTGTCACCAGAGACTTCCACA
GAAACCATCACCAGACTCCCTACCTCCAGCATAATGACAGAATCAGCAGAAATGATGATC
AAGACACAAACAGATCCTCCTGGGTCTACACCAGAGAGTACTCATACTGTGGACATATCA
ACAACACCCAACTGGGTAGAAACCCACTCGACTGTGACTCAGAGATTTTCACACTCAGAG
ATGACCACTCTTGTGAGCAGAAGCCCTGGTGATATGTTATGGCCTAGTCAATCCTCTGTG
GAAGAAACCAGCTCTGCCTCTTCCCTGCTGTCTCTGCCTGCCACGACCTCACCTTCTCCT
GTTTCCTCTACATTAGTAGAGGATTTCCCTTCCGCTTCTCTTCCTGTGACTTCTCTTCTC
AACCCTGGCCTGGTGATAACCACAGACAGGATGGGCATAAGCAGAGAACCTGGAACCAGT
TCCACTTCAAATTTGAGCAGCACCTCCCATGAGAGACTGACCACTTTGGAAGACACTGTA
GATACAGAAGACATGCAGCCTTCCACACACACAGCAGTGACCAACGTGAGGACCTCCATT
TCTGGACATGAATCACAATCTTCTGTCCTATCTGACTCAGAGACACCCAAAGCCACATCT
CCAATGGGTACCACCTACACCATGGGGGAAACGAGTGTTTCCATATCCACTTCTGACTTC
TTTGAGACCAGCAGAATTCAGATAGAACCAACATCCTCCCTGACTTCTGGATTGAGGGAG
ACCAGCAGCTCTGAGAGGATCAGCTCAGCCACAGAGGGAAGCACTGTCCTTTCTGAAGTG
CCCAGTGGTGCTACCACTGAGGTCTCCAGGACAGAAGTGATATCCTCTAGGGGAACATCC
ATGTCAGGGCCTGATCAGTTCACCATATCACCAGACATCTCTACTGAAGCGATCACCAGG
CTTTCTACTTCCCCCATTATGACAGAATCAGCAGAAAGTGCCATCACTATTGAGACAGGT
TCTCCTGGGGCTACATCAGAGGGTACCCTCACCTTGGACACCTCAACAACAACCTTTTGG
TCAGGGACCCACTCAACTGCATCTCCAGGATTTTCACACTCAGAGATGACCACTCTTATG
AGTAGAACTCCTGGAGATGTGCCATGGCCGAGCCTTCCCTCTGTGGAAGAAGCCAGCTCT
GTCTCTTCCTCACTGTCTTCACCTGCCATGACCTCAACTTCTTTTTTCTCCACATTACCA
GAGAGCATCTCCTCCTCTCCTCATCCTGTGACTGCACTTCTCACCCTTGGCCCAGTGAAG
ACCACAGACATGTTGCGCACAAGCTCAGAACCTGAAACCAGTTCACCTCCAAATTTGAGC
AGCACCTCAGCTGAAATATTAGCCACGTCTGAAGTCACCAAAGATAGAGAGAAAATTCAT
CCCTCCTCAAACACACCTGTAGTCAATGTAGGGACTGTGATTTATAAACATCTATCCCCT
TCCTCTGTTTTGGCTGACTTAGTGACAACAAAACCCACATCTCCAATGGCTACCACCTCC
ACTCTGGGGAATACAAGTGTTTCCACATCAACTCCTGCCTTCCCAGAAACTATGATGACA
CAGCCAACTTCCTCCCTGACTTCTGGATTAAGGGAGATCAGTACCTCTCAAGAGACCAGC
TCAGCAACAGAGAGAAGTGCTTCTCTTTCTGGAATGCCCACTGGTGCTACTACTAAGGTC
TCCAGAACAGAAGCCCTCTCCTTAGGCAGAACATCCACCCCAGGTCCTGCTCAATCCACA
ATATCACCAGAAATCTCCACGGAAACCATCACTAGAATTTCTACTCCCCTCACCACGACA
GGATCAGCAGAAATGACCATCACCCCCAAAACAGGTCATTCTGGGGCATCCTCACAAGGT
ACCTTTACCTTGGACACATCAAGCAGAGCCTCCTGGCCAGGAACTCACTCAGCTGCAACT
CACAGATCTCCACACTCAGGGATGACCACTCCTATGAGCAGAGGTCCTGAGGATGTGTCA
TGGCCAAGCCGCCCATCAGTGGAAAAAACTAGCCCTCCATCTTCCCTGGTGTCTTTATCT
GCAGTAACCTCACCTTCGCCACTTTATTCCACACCATCTGAGAGTAGCCACTCATCTCCT
CTCCGGGTGACTTCTCTTTTCACCCCTGTCATGATGAAGACCACAGACATGTTGGACACA
AGCTTGGAACCTGTGACCACTTCACCTCCCAGTATGAATATCACCTCAGATGAGAGTCTG
GCCACTTCTAAAGCCACCATGGAGACAGAGGCAATTCAGCTTTCAGAAAACACAGCTGTG
ACTCAGATGGGCACCATCAGCGCTAGACAAGAATTCTATTCCTCTTATCCAGGCCTCCCA
GAGCCATCCAAAGTGACATCTCCAGTGGTCACCTCTTCCACCATAAAAGACATTGTTTCT
ACAACCATACCTGCTTCCTCTGAGATAACAAGAATTGAGATGGAGTCAACATCCACCCTG
ACCCCCACACCAAGGGAGACCAGCACCTCCCAGGAGATCCACTCAGCCACAAAGCCAAGC
ACTGTTCCTTACAAGGCACTCACTAGTGCCACGATTGAGGACTCCATGACACAAGTCATG
TCCTCTAGCAGAGGACCTAGCCCTGATCAGTCCACAATGTCACAAGACATATCCACTGAA
GTGATCACCAGGCTCTCTACCTCCCCCATCAAGACAGAATCTACAGAAATGACCATTACC
ACCCAAACAGGTTCTCCTGGGGCTACATCAAGGGGTACCCTTACCTTGGACACTTCAACA
ACTTTTATGTCAGGGACCCACTCAACTGCATCTCAAGGATTTTCACACTCACAGATGACC
GCTCTTATGAGTAGAACTCCTGGAGATGTGCCATGGCTAAGCCATCCCTCTGTGGAAGAA
GCCAGCTCTGCCTCTTTCTCACTGTCTTCACCTGTCATGACCTCATCTTCTCCCGTTTCT
TCCACATTACCAGACAGCATCCACTCTTCTTCGCTTCCTGTGACATCACTTCTCACCTCA
GGGCTGGTGAAGACCACAGAGCTGTTGGGCACAAGCTCAGAACCTGAAACCAGTTCACCC
CCAAATTTGAGCAGCACCTCAGCTGAAATACTGGCCATCACTGAAGTCACTACAGATACA
GAGAAACTGGAGATGACCAATGTGGTAACCTCAGGTTATACACATGAATCTCCTTCCTCT
GTCCTAGCTGACTCAGTGACAACAAAGGCCACATCTTCAATGGGTATCACCTACCCCACA
GGAGATACAAATGTTCTCACATCAACCCCTGCCTTCTCTGACACCAGTAGGATTCAAACA
AAGTCAAAGCTCTCACTGACTCCTGGGTTGATGGAGACCAGCATCTCTGAAGAGACCAGC
TCTGCCACAGAAAAAAGCACTGTCCTTTCTAGTGTGCCCACTGGTGCTACTACTGAGGTC
TCCAGGACAGAAGCCATCTCTTCTAGCAGAACATCCATCCCAGGCCCTGCTCAATCCACA
ATGTCATCAGACACCTCCATGGAAACCATCACTAGAATTTCTACCCCCCTCACAAGGAAA
GAATCAACAGACATGGCCATCACCCCCAAAACAGGTCCTTCTGGGGCTACCTCGCAGGGT
ACCTTTACCTTGGACTCATCAAGCACAGCCTCCTGGCCAGGAACTCACTCAGCTACAACT
CAGAGATTTCCACAGTCAGTGGTGACAACTCCTATGAGCAGAGGTCCTGAGGATGTGTCA
TGGCCAAGCCCGCTGTCTGTGGAAAAAAACAGCCCTCCATCTTCCCTGGTATCTTCATCT
TCAGTAACCTCACCTTCGCCACTTTATTCCACACCATCTGGGAGTAGCCACTCCTCTCCT
GTCCCTGTCACTTCTCTTTTCACCTCTATCATGATGAAGGCCACAGACATGTTGGATGCA
AGTTTGGAACCTGAGACCACTTCAGCTCCCAATATGAATATCACCTCAGATGAGAGTCTG
GCCGCTTCTAAAGCCACCACGGAGACAGAGGCAATTCACGTTTTTGAAAATACAGCAGCG
TCCCATGTGGAAACCACCAGTGCTACAGAGGAACTCTATTCCTCTTCCCCAGGCTTCTCA
GAGCCAACAAAAGTGATATCTCCAGTGGTCACCTCTTCCTCTATAAGAGACAACATGGTT
TCCACAACAATGCCTGGCTCCTCTGGCATTACAAGGATTGAGATAGAGTCAATGTCATCT
CTGACCCCTGGACTGAGGGAGACCAGAACCTCCCAGGACATCACCTCATCCACAGAGACA
AGCACTGTCCTTTACAAGATGCCCTCTGGTGCCACTCCTGAGGTCTCCAGGACAGAAGTT
ATGCCCTCTAGCAGAACATCCATTCCTGGCCCTGCTCAGTCCACAATGTCACTAGACATC
TCCGATGAAGTTGTCACCAGGCTGTCTACCTCTCCCATCATGACAGAATCTGCAGAAATA
ACCATCACCACCCAAACAGGTTATTCTCTGGCTACATCCCAGGTTACCCTTCCCTTGGGC
ACCTCAATGACCTTTTTGTCAGGGACCCACTCAACTATGTCTCAAGGACTTTCACACTCA
GAGATGACCAATCTTATGAGCAGGGGTCCTGAAAGTCTGTCATGGACGAGCCCTCGCTTT
GTGGAAACAACTAGATCTTCCTCTTCTCTGACATCATTACCTCTCACGACCTCACTTTCT
CCTGTGTCCTCCACATTACTAGACAGTAGCCCCTCCTCTCCTCTTCCTGTGACTTCACTT
ATCCTCCCAGGCCTGGTGAAGACTACAGAAGTGTTGGATACAAGCTCAGAGCCTAAAACC
AGTTCATCTCCAAATTTGAGCAGCACCTCAGTTGAAATACCGGCCACCTCTGAAATCATG
ACAGATACAGAGAAAATTCATCCTTCCTCAAACACAGCGGTGGCCAAAGTGAGGACCTCC
AGTTCTGTTCATGAATCTCATTCCTCTGTCCTAGCTGACTCAGAAACAACCATAACCATA
CCTTCAATGGGTATCACCTCCGCTGTGGACGATACCACTGTTTTCACATCAAATCCTGCC
TTCTCTGAGACTAGGAGGATTCCGACAGAGCCAACATTCTCATTGACTCCTGGATTCAGG
GAGACTAGCACCTCTGAAGAGACCACCTCAATCACAGAAACAAGTGCAGTCCTTTATGGA
GTGCCCACTAGTGCTACTACTGAAGTCTCCATGACAGAAATCATGTCCTCTAATAGAATA
CACATCCCTGACTCTGATCAGTCCACGATGTCTCCAGACATCATCACTGAAGTGATCACC
AGGCTCTCTTCCTCATCCATGATGTCAGAATCAACACAAATGACCATCACCACCCAAAAA
AGTTCTCCTGGGGCTACAGCACAGAGTACTCTTACCTTGGCCACAACAACAGCCCCCTTG
GCAAGGACCCACTCAACTGTTCCTCCTAGATTTTTACACTCAGAGATGACAACTCTTATG
AGTAGGAGTCCTGAAAATCCATCATGGAAGAGCTCTCTCTTTGTGGAAAAAACTAGCTCT
TCATCTTCTCTGTTGTCCTTACCTGTCACGACCTCACCTTCTGTTTCTTCCACATTACCG
CAGAGTATCCCTTCCTCCTCTTTTTCTGTGACTTCACTCCTCACCCCAGGCATGGTGAAG
ACTACAGACACAAGCACAGAACCTGGAACCAGTTTATCTCCAAATCTGAGTGGCACCTCA
GTTGAAATACTGGCTGCCTCTGAAGTCACCACAGATACAGAGAAAATTCATCCTTCTTCA
AGCATGGCAGTGACCAATGTGGGAACCACCAGTTCTGGACATGAACTATATTCCTCTGTT
TCAATCCACTCGGAGCCATCCAAGGCTACATACCCAGTGGGTACTCCCTCTTCCATGGCT
GAAACCTCTATTTCCACATCAATGCCTGCTAATTTTGAGACCACAGGATTTGAGGCTGAG
CCATTTTCTCATTTGACTTCTGGATTTAGGAAGACAAACATGTCCCTGGACACCAGCTCA
GTCACACCAACAAATACACCTTCTTCTCCTGGGTCCACTCACCTTTTACAGAGTTCCAAG
ACTGATTTCACCTCTTCTGCAAAAACATCATCCCCAGACTGGCCTCCAGCCTCACAGTAT
ACTGAAATTCCAGTGGACATAATCACCCCCTTTAATGCTTCTCCATCTATTACGGAGTCC
ACTGGGATAACCTCCTTCCCAGAATCCAGGTTTACTATGTCTGTAACAGAAAGTACTCAT
CATCTGAGTACAGATTTGCTGCCTTCAGCTGAGACTATTTCCACTGGCACAGTGATGCCT
TCTCTATCAGAGGCCATGACTTCATTTGCCACCACTGGAGTTCCACGAGCCATCTCAGGT
TCAGGTAGTCCATTCTCTAGGACAGAGTCAGGCCCTGGGGATGCTACTCTGTCCACCATT
GCAGAGAGCCTGCCTTCATCCACTCCTGTGCCATTCTCCTCTTCAACCTTCACTACCACT
GATTCTTCAACCATCCCAGCCCTCCATGAGATAACTTCCTCTTCAGCTACCCCATATAGA
GTGGACACCAGTCTTGGGACAGAGAGCAGCACTACTGAAGGACGCTTGGTTATGGTCAGT
ACTTTGGACACTTCAAGCCAACCAGGCAGGACATCTTCATCACCCATTTTGGATACCAGA
ATGACAGAGAGCGTTGAGCTGGGAACAGTGACAAGTGCTTATCAAGTTCCTTCACTCTCA
ACACGGTTGACAAGAACTGATGGCATTATGGAACACATCACAAAAATACCCAATGAAGCA
GCACACAGAGGTACCATAAGACCAGTCAAAGGCCCTCAGACATCCACTTCGCCTGCCAGT
CCTAAAGGACTACACACAGGAGGGACAAAAAGAATGGAGACCACCACCACAGCTCTGAAG
ACCACCACCACAGCTCTGAAGACCACTTCCAGAGCCACCTTGACCACCAGTGTCTATACT
CCCACTTTGGGAACACTGACTCCCCTCAATGCATCAATGCAAATGGCCAGCACAATCCCC
ACAGAAATGATGATCACAACCCCATATGTTTTCCCTGATGTTCCAGAAACGACATCCTCA
TTGGCTACCAGCCTGGGAGCAGAAACCAGCACAGCTCTTCCCAGGACAACCCCATCTGTT
TTCAATAGAGAATCAGAGACCACAGCCTCACTGGTCTCTCGTTCTGGGGCAGAGAGAAGT
CCGGTTATTCAAACTCTAGATGTTTCTTCTAGTGAGCCAGATACAACAGCTTCATGGGTT
ATCCATCCTGCAGAGACCATCCCAACTGTTTCCAAGACAACCCCCAATTTTTTCCACAGT
GAATTAGACACTGTATCTTCCACAGCCACCAGTCATGGGGCAGACGTCAGCTCAGCCATT
CCAACAAATATCTCACCTAGTGAACTAGATGCACTGACCCCACTGGTCACTATTTCGGGG
ACAGATACTAGTACAACATTCCCAACACTGACTAAGTCCCCACATGAAACAGAGACAAGA
ACCACATGGCTCACTCATCCTGCAGAGACCAGCTCAACTATTCCCAGAACAATCCCCAAT
TTTTCTCATCATGAATCAGATGCCACACCTTCAATAGCCACCAGTCCTGGGGCAGAAACC
AGTTCAGCTATTCCAATTATGACTGTCTCACCTGGTGCAGAAGATCTGGTGACCTCACAG
GTCACTAGTTCTGGGACAGACAGAAATATGACTATTCCAACTTTGACTCTTTCTCCTGGT
GAACCAAAGACGATAGCCTCATTAGTCACCCATCCTGAAGCACAGACAAGTTCGGCCATT
CCAACTTCAACTATCTCGCCTGCTGTATCACGGTTGGTGACCTCAATGGTCACCAGTTTG
GCGGCAAAGACAAGTACAACTAATCGAGCTCTGACAAACTCCCCTGGTGAACCAGCTACA
ACAGTTTCATTGGTCACGCATCCTGCACAGACCAGCCCAACAGTTCCCTGGACAACTTCC
ATTTTTTTCCATAGTAAATCAGACACCACACCTTCAATGACCACCAGTCATGGGGCAGAA
TCCAGTTCAGCTGTTCCAACTCCAACTGTTTCAACTGAGGTACCAGGAGTAGTGACCCCT
TTGGTCACCAGTTCTAGGGCAGTGATCAGTACAACTATTCCAATTCTGACTCTTTCTCCT
GGTGAACCAGAGACCACACCTTCAATGGCCACCAGTCATGGGGAAGAAGCCAGTTCTGCT
ATTCCAACTCCAACTGTTTCACCTGGGGTACCAGGAGTGGTGACCTCTCTGGTCACTAGT
TCTAGGGCAGTGACTAGTACAACTATTCCAATTCTGACTTTTTCTCTTGGTGAACCAGAG
ACCACACCTTCAATGGCCACCAGTCATGGGACAGAAGCTGGCTCAGCTGTTCCAACTGTT
TTACCTGAGGTACCAGGAATGGTGACCTCTCTGGTTGCTAGTTCTAGGGCAGTAACCAGT
ACAACTCTTCCAACTCTGACTCTTTCTCCTGGTGAACCAGAGACCACACCTTCAATGGCC
ACCAGTCATGGGGCAGAAGCCAGCTCAACTGTTCCAACTGTTTCACCTGAGGTACCAGGA
GTGGTGACCTCTCTGGTCACTAGTTCTAGTGGAGTAAACAGTACAAGTATTCCAACTCTG
ATTCTTTCTCCTGGTGAACTAGAAACCACACCTTCAATGGCCACCAGTCATGGGGCAGAA
GCCAGCTCAGCTGTTCCAACTCCAACTGTTTCACCTGGGGTATCAGGAGTGGTGACCCCT
CTGGTCACTAGTTCCAGGGCAGTGACCAGTACAACTATTCCAATTCTAACTCTTTCTTCT
AGTGAGCCAGAGACCACACCTTCAATGGCCACCAGTCATGGGGTAGAAGCCAGCTCAGCT
GTTCTAACTGTTTCACCTGAGGTACCAGGAATGGTGACCTCTCTGGTCACTAGTTCTAGA
GCAGTAACCAGTACAACTATTCCAACTCTGACTATTTCTTCTGATGAACCAGAGACCACA
ACTTCATTGGTCACCCATTCTGAGGCAAAGATGATTTCAGCCATTCCAACTTTAGCTGTC
TCCCCTACTGTACAAGGGCTGGTGACTTCACTGGTCACTAGTTCTGGGTCAGAGACCAGT
GCGTTTTCAAATCTAACTGTTGCCTCAAGTCAACCAGAGACCATAGACTCATGGGTCGCT
CATCCTGGGACAGAAGCAAGTTCTGTTGTTCCAACTTTGACTGTCTCCACTGGTGAGCCG
TTTACAAATATCTCATTGGTCACCCATCCTGCAGAGAGTAGCTCAACTCTTCCCAGGACA
ACCTCAAGGTTTTCCCACAGTGAATTAGACACTATGCCTTCTACAGTCACCAGTCCTGAG
GCAGAATCCAGCTCAGCCATTTCAACAACTATTTCACCTGGTATACCAGGTGTGCTGACA
TCACTGGTCACTAGCTCTGGGAGAGACATCAGTGCAACTTTTCCAACAGTGCCTGAGTCC
CCACATGAATCAGAGGCAACAGCCTCATGGGTTACTCATCCTGCAGTCACCAGCACAACA
GTTCCCAGGACAACCCCTAATTATTCTCATAGTGAACCAGACACCACACCATCAATAGCC
ACCAGTCCTGGGGCAGAAGCCACTTCAGATTTTCCAACAATAACTGTCTCACCTGATGTA
CCAGATATGGTAACCTCACAGGTCACTAGTTCTGGGACAGACACCAGTATAACTATTCCA
ACTCTGACTCTTTCTTCTGGTGAGCCAGAGACCACAACCTCATTTATCACCTATTCTGAG
ACACACACAAGTTCAGCCATTCCAACTCTCCCTGTCTCCCCTGGTGCATCAAAGATGCTG
ACCTCACTGGTCATCAGTTCTGGGACAGACAGCACTACAACTTTCCCAACACTGACGGAG
ACCCCATATGAACCAGAGACAACAGCCATACAGCTCATTCATCCTGCAGAGACCAACACA
ATGGTTCCCAGGACAACTCCCAAGTTTTCCCATAGTAAGTCAGACACCACACTCCCAGTA
GCCATCACCAGTCCTGGGCCAGAAGCCAGTTCAGCTGTTTCAACGACAACTATCTCACCT
GATATGTCAGATCTGGTGACCTCACTGGTCCCTAGTTCTGGGACAGACACCAGTACAACC
TTCCCAACATTGAGTGAGACCCCATATGAACCAGAGACTACAGCCACGTGGCTCACTCAT
CCTGCAGAAACCAGCACAACGGTTTCTGGGACAATTCCCAACTTTTCCCATAGGGGATCA
GACACTGCACCCTCAATGGTCACCAGTCCTGGAGTAGACACGAGGTCAGGTGTTCCAACT
ACAACCATCCCACCCAGTATACCAGGGGTAGTGACCTCACAGGTCACTAGTTCTGCAACA
GACACTAGTACAGCTATTCCAACTTTGACTCCTTCTCCTGGTGAACCAGAGACCACAGCC
TCATCAGCTACCCATCCTGGGACACAGACTGGCTTCACTGTTCCAATTCGGACTGTTCCC
TCTAGTGAGCCAGATACAATGGCTTCCTGGGTCACTCATCCTCCACAGACCAGCACACCT
GTTTCCAGAACAACCTCCAGTTTTTCCCATAGTAGTCCAGATGCCACACCTGTAATGGCC
ACCAGTCCTAGGACAGAAGCCAGTTCAGCTGTACTGACAACAATCTCACCTGGTGCACCA
GAGATGGTGACTTCACAGATCACTAGTTCTGGGGCAGCAACCAGTACAACTGTTCCAACT
TTGACTCATTCTCCTGGTATGCCAGAGACCACAGCCTTATTGAGCACCCATCCCAGAACA
GAGACAAGTAAAACATTTCCTGCTTCAACTGTGTTTCCTCAAGTATCAGAGACCACAGCC
TCACTCACCATTAGACCTGGTGCAGAGACTAGCACAGCTCTCCCAACTCAGACAACATCC
TCTCTCTTCACCCTACTTGTAACTGGAACCAGCAGAGTTGATCTAAGTCCAACTGCTTCA
CCTGGTGTTTCTGCAAAAACAGCCCCACTTTCCACCCATCCAGGGACAGAAACCAGCACA
ATGATTCCAACTTCAACTCTTTCCCTTGGTTTACTAGAGACTACAGGCTTACTGGCCACC
AGCTCTTCAGCAGAGACCAGCACGAGTACTCTAACTCTGACTGTTTCCCCTGCTGTCTCT
GGGCTTTCCAGTGCCTCTATAACAACTGATAAGCCCCAAACTGTGACCTCCTGGAACACA
GAAACCTCACCATCTGTAACTTCAGTTGGACCCCCAGAATTTTCCAGGACTGTCACAGGC
ACCACTATGACCTTGATACCATCAGAGATGCCAACACCACCTAAAACCAGTCATGGAGAA
GGAGTGAGTCCAACCACTATCTTGAGAACTACAATGGTTGAAGCCACTAATTTAGCTACC
ACAGGTTCCAGTCCCACTGTGGCCAAGACAACAACCACCTTCAATACACTGGCTGGAAGC
CTCTTTACTCCTCTGACCACACCTGGGATGTCCACCTTGGCCTCTGAGAGTGTGACCTCA
AGAACAAGTTATAACCATCGGTCCTGGATCTCCACCACCAGCAGTTATAACCGTCGGTAC
TGGACCCCTGCCACCAGCACTCCAGTGACTTCTACATTCTCCCCAGGGATTTCCACATCC
TCCATCCCCAGCTCCACAGCAGCCACAGTCCCATTCATGGTGCCATTCACCCTCAACTTC
ACCATCACCAACCTGCAGTACGAGGAGGACATGCGGCACCCTGGTTCCAGGAAGTTCAAC
GCCACAGAGAGAGAACTGCAGGGTCTGCTCAAACCCTTGTTCAGGAATAGCAGTCTGGAA
TACCTCTATTCAGGCTGCAGACTAGCCTCACTCAGGCCAGAGAAGGATAGCTCAGCCACG
GCAGTGGATGCCATCTGCACACATCGCCCTGACCCTGAAGACCTCGGACTGGACAGAGAG
CGACTGTACTGGGAGCTGAGCAATCTGACAAATGGCATCCAGGAGCTGGGCCCCTACACC
CTGGACCGGAACAGTCTCTATGTCAATGGTTTCACCCATCGAAGCTCTATGCCCACCACC
AGCACTCCTGGGACCTCCACAGTGGATGTGGGAACCTCAGGGACTCCATCCTCCAGCCCC
AGCCCCACGACTGCTGGCCCTCTCCTGATGCCGTTCACCCTCAACTTCACCATCACCAAC
CTGCAGTACGAGGAGGACATGCGTCGCACTGGCTCCAGGAAGTTCAACACCATGGAGAGT
GTCCTGCAGGGTCTGCTCAAGCCCTTGTTCAAGAACACCAGTGTTGGCCCTCTGTACTCT
GGCTGCAGATTGACCTTGCTCAGGCCCGAGAAAGATGGGGCAGCCACTGGAGTGGATGCC
ATCTGCACCCACCGCCTTGACCCCAAAAGCCCTGGACTCAACAGGGAGCAGCTGTACTGG
GAGCTAAGCAAACTGACCAATGACATTGAAGAGCTGGGCCCCTACACCCTGGACAGGAAC
AGTCTCTATGTCAATGGTTTCACCCATCAGAGCTCTGTGTCCACCACCAGCACTCCTGGG
ACCTCCACAGTGGATCTCAGAACCTCAGGGACTCCATCCTCCCTCTCCAGCCCCACAATT
ATGGCTGCTGGCCCTCTCCTGGTACCATTCACCCTCAACTTCACCATCACCAACCTGCAG
TATGGGGAGGACATGGGTCACCCTGGCTCCAGGAAGTTCAACACCACAGAGAGGGTCCTG
CAGGGTCTGCTTGGTCCCATATTCAAGAACACCAGTGTTGGCCCTCTGTACTCTGGCTGC
AGACTGACCTCTCTCAGGTCTGAGAAGGATGGAGCAGCCACTGGAGTGGATGCCATCTGC
ATCCATCATCTTGACCCCAAAAGCCCTGGACTCAACAGAGAGCGGCTGTACTGGGAGCTG
AGCCAACTGACCAATGGCATCAAAGAGCTGGGCCCCTACACCCTGGACAGGAACAGTCTC
TATGTCAATGGTTTCACCCATCGGACCTCTGTGCCCACCAGCAGCACTCCTGGGACCTCC
ACAGTGGACCTTGGAACCTCAGGGACTCCATTCTCCCTCCCAAGCCCCGCAACTGCTGGC
CCTCTCCTGGTGCTGTTCACCCTCAACTTCACCATCACCAACCTGAAGTATGAGGAGGAC
ATGCATCGCCCTGGCTCCAGGAAGTTCAACACCACTGAGAGGGTCCTGCAGACTCTGCTT
GGTCCTATGTTCAAGAACACCAGTGTTGGCCTTCTGTACTCTGGCTGCAGACTGACCTTG
CTCAGGTCCGAGAAGGATGGAGCAGCCACTGGAGTGGATGCCATCTGCACCCACCGTCTT
GACCCCAAAAGCCCTGGAGTGGACAGGGAGCAGCTATACTGGGAGCTGAGCCAGCTGACC
AATGGCATCAAAGAGCTGGGCCCCTACACCCTGGACAGGAACAGTCTCTATGTCAATGGT
TTCACCCATTGGATCCCTGTGCCCACCAGCAGCACTCCTGGGACCTCCACAGTGGACCTT
GGGTCAGGGACTCCATCCTCCCTCCCCAGCCCCACAACTGCTGGCCCTCTCCTGGTGCCG
TTCACCCTCAACTTCACCATCACCAACCTGAAGTACGAGGAGGACATGCATTGCCCTGGC
TCCAGGAAGTTCAACACCACAGAGAGAGTCCTGCAGAGTCTGCTTGGTCCCATGTTCAAG
AACACCAGTGTTGGCCCTCTGTACTCTGGCTGCAGACTGACCTTGCTCAGGTCCGAGAAG
GATGGAGCAGCCACTGGAGTGGATGCCATCTGCACCCACCGTCTTGACCCCAAAAGCCCT
GGAGTGGACAGGGAGCAGCTATACTGGGAGCTGAGCCAGCTGACCAATGGCATCAAAGAG
CTGGGTCCCTACACCCTGGACAGAAACAGTCTCTATGTCAATGGTTTCACCCATCAGACC
TCTGCGCCCAACACCAGCACTCCTGGGACCTCCACAGTGGACCTTGGGACCTCAGGGACT
CCATCCTCCCTCCCCAGCCCTACATCTGCTGGCCCTCTCCTGGTGCCATTCACCCTCAAC
TTCACCATCACCAACCTGCAGTACGAGGAGGACATGCATCACCCAGGCTCCAGGAAGTTC
AACACCACGGAGCGGGTCCTGCAGGGTCTGCTTGGTCCCATGTTCAAGAACACCAGTGTC
GGCCTTCTGTACTCTGGCTGCAGACTGACCTTGCTCAGGCCTGAGAAGAATGGGGCAGCC
ACTGGAATGGATGCCATCTGCAGCCACCGTCTTGACCCCAAAAGCCCTGGACTCAACAGA
GAGCAGCTGTACTGGGAGCTGAGCCAGCTGACCCATGGCATCAAAGAGCTGGGCCCCTAC
ACCCTGGACAGGAACAGTCTCTATGTCAATGGTTTCACCCATCGGAGCTCTGTGGCCCCC
ACCAGCACTCCTGGGACCTCCACAGTGGACCTTGGGACCTCAGGGACTCCATCCTCCCTC
CCCAGCCCCACAACAGCTGTTCCTCTCCTGGTGCCGTTCACCCTCAACTTTACCATCACC
AATCTGCAGTATGGGGAGGACATGCGTCACCCTGGCTCCAGGAAGTTCAACACCACAGAG
AGGGTCCTGCAGGGTCTGCTTGGTCCCTTGTTCAAGAACTCCAGTGTCGGCCCTCTGTAC
TCTGGCTGCAGACTGATCTCTCTCAGGTCTGAGAAGGATGGGGCAGCCACTGGAGTGGAT
GCCATCTGCACCCACCACCTTAACCCTCAAAGCCCTGGACTGGACAGGGAGCAGCTGTAC
TGGCAGCTGAGCCAGATGACCAATGGCATCAAAGAGCTGGGCCCCTACACCCTGGACCGG
AACAGTCTCTACGTCAATGGTTTCACCCATCGGAGCTCTGGGCTCACCACCAGCACTCCT
TGGACTTCCACAGTTGACCTTGGAACCTCAGGGACTCCATCCCCCGTCCCCAGCCCCACA
ACCACCGGCCCTCTCCTGGTGCCATTCACACTCAACTTCACCATCACTAACCTACAGTAT
GAGGAGAACATGGGTCACCCTGGCTCCAGGAAGTTCAACATCACGGAGAGTGTTCTGCAG
GGTCTGCTCAAGCCCTTGTTCAAGAGCACCAGTGTTGGCCCTCTGTATTCTGGCTGCAGA
CTGACCTTGCTCAGGCCTGAGAAGGATGGAGTAGCCACCAGAGTGGACGCCATCTGCACC
CACCGCCCTGACCCCAAAATCCCTGGGCTAGACAGACAGCAGCTATACTGGGAGCTGAGC
CAGCTGACCCACAGCATCACTGAGCTGGGACCCTACACCCTGGATAGGGACAGTCTCTAT
GTCAATGGTTTCACCCAGCGGAGCTCTGTGCCCACCACCAGCACTCCTGGGACTTTCACA
GTACAGCCGGAAACCTCTGAGACTCCATCATCCCTCCCTGGCCCCACAGCCACTGGCCCT
GTCCTGCTGCCATTCACCCTCAATTTTACCATCACTAACCTGCAGTATGAGGAGGACATG
CGTCGCCCTGGCTCCAGGAAGTTCAACACCACGGAGAGGGTCCTTCAGGGTCTGCTTATG
CCCTTGTTCAAGAACACCAGTGTCAGCTCTCTGTACTCTGGTTGCAGACTGACCTTGCTC
AGGCCTGAGAAGGATGGGGCAGCCACCAGAGTGGATGCTGTCTGCACCCATCGTCCTGAC
CCCAAAAGCCCTGGACTGGACAGAGAGCGGCTGTACTGGAAGCTGAGCCAGCTGACCCAC
GGCATCACTGAGCTGGGCCCCTACACCCTGGACAGGCACAGTCTCTATGTCAATGGTTTC
ACCCATCAGAGCTCTATGACGACCACCAGAACTCCTGATACCTCCACAATGCACCTGGCA
ACCTCGAGAACTCCAGCCTCCCTGTCTGGACCCATGACCGCCAGCCCTCTCCTGGTGCTA
TTCACAATTAACTTCACCATCACTAACCTGCGGTATGAGGAGAACATGCATCACCCTGGC
TCTAGAAAGTTTAACACCACGGAGAGAGTCCTTCAGGGTCTGCTCAGGCCTGTGTTCAAG
AACACCAGTGTTGGCCCTCTGTACTCTGGCTGCAGACTGACCTTGCTCAGGCCCAAGAAG
GATGGGGCAGCCACCAAAGTGGATGCCATCTGCACCTACCGCCCTGATCCCAAAAGCCCT
GGACTGGACAGAGAGCAGCTATACTGGGAGCTGAGCCAGCTGACCCACAGCATCACTGAG
CTGGGCCCCTACACCCTGGACAGGGACAGTCTCTATGTCAATGGTTTCACACAGCGGAGC
TCTGTGCCCACCACTAGCATTCCTGGGACCCCCACAGTGGACCTGGGAACATCTGGGACT
CCAGTTTCTAAACCTGGTCCCTCGGCTGCCAGCCCTCTCCTGGTGCTATTCACTCTCAAC
TTCACCATCACCAACCTGCGGTATGAGGAGAACATGCAGCACCCTGGCTCCAGGAAGTTC
AACACCACGGAGAGGGTCCTTCAGGGCCTGCTCAGGTCCCTGTTCAAGAGCACCAGTGTT
GGCCCTCTGTACTCTGGCTGCAGACTGACTTTGCTCAGGCCTGAAAAGGATGGGACAGCC
ACTGGAGTGGATGCCATCTGCACCCACCACCCTGACCCCAAAAGCCCTAGGCTGGACAGA
GAGCAGCTGTATTGGGAGCTGAGCCAGCTGACCCACAATATCACTGAGCTGGGCCCCTAT
GCCCTGGACAACGACAGCCTCTTTGTCAATGGTTTCACTCATCGGAGCTCTGTGTCCACC
ACCAGCACTCCTGGGACCCCCACAGTGTATCTGGGAGCATCTAAGACTCCAGCCTCGATA
TTTGGCCCTTCAGCTGCCAGCCATCTCCTGATACTATTCACCCTCAACTTCACCATCACT
AACCTGCGGTATGAGGAGAACATGTGGCCTGGCTCCAGGAAGTTCAACACTACAGAGAGG
GTCCTTCAGGGCCTGCTAAGGCCCTTGTTCAAGAACACCAGTGTTGGCCCTCTGTACTCT
GGCTGCAGGCTGACCTTGCTCAGGCCAGAGAAAGATGGGGAAGCCACCGGAGTGGATGCC
ATCTGCACCCACCGCCCTGACCCCACAGGCCCTGGGCTGGACAGAGAGCAGCTGTATTTG
GAGCTGAGCCAGCTGACCCACAGCATCACTGAGCTGGGCCCCTACACACTGGACAGGGAC
AGTCTCTATGTCAATGGTTTCACCCATCGGAGCTCTGTACCCACCACCAGCACCGGGGTG
GTCAGCGAGGAGCCATTCACACTGAACTTCACCATCAACAACCTGCGCTACATGGCGGAC
ATGGGCCAACCCGGCTCCCTCAAGTTCAACATCACAGACAACGTCATGCAGCACCTGCTC
AGTCCTTTGTTCCAGAGGAGCAGCCTGGGTGCACGGTACACAGGCTGCAGGGTCATCGCA
CTAAGGTCTGTGAAGAACGGTGCTGAGACACGGGTGGACCTCCTCTGCACCTACCTGCAG
CCCCTCAGCGGCCCAGGTCTGCCTATCAAGCAGGTGTTCCATGAGCTGAGCCAGCAGACC
CATGGCATCACCCGGCTGGGCCCCTACTCTCTGGACAAAGACAGCCTCTACCTTAACGGT
TACAATGAACCTGGTCCAGATGAGCCTCCTACAACTCCCAAGCCAGCCACCACATTCCTG
CCTCCTCTGTCAGAAGCCACAACAGCCATGGGGTACCACCTGAAGACCCTCACACTCAAC
TTCACCATCTCCAATCTCCAGTATTCACCAGATATGGGCAAGGGCTCAGCTACATTCAAC
TCCACCGAGGGGGTCCTTCAGCACCTGCTCAGACCCTTGTTCCAGAAGAGCAGCATGGGC
CCCTTCTACTTGGGTTGCCAACTGATCTCCCTCAGGCCTGAGAAGGATGGGGCAGCCACT
GGTGTGGACACCACCTGCACCTACCACCCTGACCCTGTGGGCCCCGGGCTGGACATACAG
CAGCTTTACTGGGAGCTGAGTCAGCTGACCCATGGTGTCACCCAACTGGGCTTCTATGTC
CTGGACAGGGATAGCCTCTTCATCAATGGCTATGCACCCCAGAATTTATCAATCCGGGGC
GAGTACCAGATAAATTTCCACATTGTCAACTGGAACCTCAGTAATCCAGACCCCACATCC
TCAGAGTACATCACCCTGCTGAGGGACATCCAGGACAAGGTCACCACACTCTACAAAGGC
AGTCAACTACATGACACATTCCGCTTCTGCCTGGTCACCAACTTGACGATGGACTCCGTG
TTGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGACCCCAGCCTGGTGGAGCAAGTC
TTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCTGGGCTCCACCTACCAGTTGGTG
GACATCCATGTGACAGAAATGGAGTCATCAGTTTATCAACCAACAAGCAGCTCCAGCACC
CAGCACTTCTACCTGAATTTCACCATCACCAACCTACCATATTCCCAGGACAAAGCCCAG
CCAGGCACCACCAATTACCAGAGGAACAAAAGGAATATTGAGGATGCGCTCAACCAACTC
TTCCGAAACAGCAGCATCAAGAGTTATTTTTCTGACTGTCAAGTTTCAACATTCAGGTCT
GTCCCCAACAGGCACCACACCGGGGTGGACTCCCTGTGTAACTTCTCGCCACTGGCTCGG
AGAGTAGACAGAGTTGCCATCTATGAGGAATTTCTGCGGATGACCCGGAATGGTACCCAG
CTGCAGAACTTCACCCTGGACAGGAGCAGTGTCCTTGTGGATGGGTATTCTCCCAACAGA
AATGAGCCCTTAACTGGGAATTCTGACCTTCCCTTCTGGGCTGTCATCCTCATCGGCTTG
GCAGGACTCCTGGGAGTCATCACATGCCTGATCTGCGGTGTCCTGGTGACCACCCGCCGG
CGGAAGAAGGAAGGAGAATACAACGTCCAGCAACAGTGCCCAGGCTACTACCAGTCACAC
CTAGACCTGGAGGATCTGCAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01390</identifier>
            <name>SEA</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>O-glycan processing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>